The Chr X-linked Gct6 locus: A granulosa cell tumor suppressor in mice by Rabie, Zoha
  
 
 
The Chr X-linked Gct6 locus:  
A granulosa cell tumor suppressor in mice 
 
 
by  
© Zoha Rabie, B.Sc. 
 
 
 
A thesis submitted to the 
School of Graduate Studies 
in partial fulfillment of the requirements 
for the degree of 
Master of Science in Medicine 
 
 
 
 
 
 
Faculty of Medicine 
Memorial University of Newfoundland 
 
May 2015 
St. John’s, NL 
i 
Abstract 
Juvenile-type granulosa cell tumors (GCT) originate in the somatic tissues that surround 
the germ cells of the ovarian follicle in children and young women. Unlike Adult-type GCT that 
share a common, acquired mutation in the FOXL2 gene, the genetic determinants for juvenile-
type GCT susceptibility are not so well defined. A spontaneous, early-onset GCT phenotype in 
SWR inbred female mice has revealed multiple Gct loci: Gct1 on Chromosome (Chr) 4 initiates 
the tumorigenic program; Gct4 on Chr X modifies trait penetrance and Gct6 on Chr X is a 
suppressor of GCT initiation. The Gct6 locus has been mapped to a 1.02 million base pair region 
with over 20 annotated genes. Two complementary approaches were taken to help 
prioritize Gct6 gene candidates. First, a congenic strain approach was taken to determine the 
tumor suppressor phenotype of the Gct6C57 allele in SWR.C57-X females. Second, a whole-locus 
capture and Next Generation Sequencing (NGS) protocol was applied to identify all nucleotide 
variations between SWR (tumor-susceptible SW) and Castaneus (CAST; tumor-resistant CA) 
alleles vs. the C57BL/6J (C57) genome. The congenic strain data supported the hypothesis that a 
common Gct6 tumor suppressor allele in C57 and CAST genomes was distinct from the 
permissive Gct6SW allele, which reduced the prioritized list of NGS variants (SNPs, INDELs) to 
746. Priority was given to non-synonymous variants identified in the coding region of 5 
candidate genes: BC065397, Esx1, Slc25a53, Tmsb15b1 and Tmsb15l. Sanger sequencing 
confirmed the 5 non-synonymous variants between C57 and SWR strains and identified a novel 
28 bp deletion in the coding region of the Slc25a53 gene. Allele association analysis between 5 
Gct6 permissive and 2 Gct6 suppressive strains demonstrated that the 5 non-synonymous 
variants were not conserved between permissive strains.  However, all 5 permissive strains tested 
(SWR, SJL/J, PL/J, BUB/BnJ, ST/bJ) had deletion mutations with inferred deleterious frameshift 
effect in the Slc25a53 gene when compared to the GC tumor suppressive strains (CAST and 
C57), making Slc25a53 a promising candidate for shared identity with Gct6. 
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 1.0 Introduction 
1.1 The Ovary 
1.1.1 Ovarian Anatomy and Physiology 
The ovary is a specialized female reproductive organ with two major functions, 
gametogenesis and steroidogenesis. Gametogenesis is the production and release of mature 
haploid gametes whereas steroidogenesis is the production and release of steroid hormones. To 
perform its specialised functions, the ovary is composed of germ cells (oocytes) and companion 
somatic cells. The germ cells help establish follicular organization and the lack of germ cells in 
the developing ovaries results in the absence of the formation of ovarian follicles (Piprek, 2009).  
The ovary is composed of two general regions: the inner medulla, a highly vascularized 
region that contains lymphatic vessels, nerves, and connective tissue, and the outer cortex, where 
follicles proceed along a course of maturation under hormonal control (Figure 1.1). An ovarian 
follicle is made up of an oocyte, surrounded by granulosa cell layers (GCs), and an outer 
basement membrane (BM) surrounded by additional layers of thecal cells (TCs). Working 
together, TCs and GCs synthesize estrogen to control the maturation of additional follicles, 
promote the appearance of the secondary sex characteristics of females at puberty, maintain a 
woman’s reproductive organs in their mature functional state, and influence the ovarian cycle. 
Upon cessation of woman's reproductive ability and exhaustion of the follicular pool menopause 
occurs.  
During the female reproductive years, the normal functions of the ovary are controlled by 
a series of complex interactions between the hypothalamus, the anterior pituitary gland and 
13 
locally produced factors in the gonad such as hormones, growth factors, and cytokines (Figure 
1.2).  
 
 
 
Figure 1.1 Human ovarian anatomy and cellular components 
The ovary is held in place by the ovarian ligament and suspensory ligament. The cortex of the ovary is covered by a 
layer of epithelium, while the inner most region of the ovary is highly vascularised and contains maturing and 
resting follicles, lymphatic vessels, nerves, and connective tissue. The ovary is covered by surface epithelium; 
beneath the surface epithelium is tunica albuginea which is the connective tissue covering of the ovaries. The zona 
pellucida is a glycoprotein layer surrounding the plasma membrane of oocytes. During follicogenesis, an ovarian 
follicle passes through the following stages: primordial, primary, secondary (pre-antral), tertiary (antral) and finally 
the pre-ovulatory (Vesicular) follicle stage. The formation of a fluid-filled cavity adjacent to the oocyte called 
the antrum designates the follicle as an antral follicle. Upon ovulation and the release of the mature egg from the 
ovary, the remaining follicular GCs undergo luteinisation and switch from estrogen to progesterone production 
(corpus luteum) to maintain early pregnancy. Copyright © 2010 by The McGraw-Hill Companies, Inc, printed with 
permission, Appendix D (a).  
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Figure 1.2 Hypothalamic-pituitary-gonadal (HPG) axis  
The function of normal ovary is controlled by complex interactions between the hypothalamus, the anterior-pituitary 
and locally produced factors such as hormones, growth factors, and cytokines. GnRH released from hypothalamus 
travels to anterior pituitary which stimulates secretion of LH and FSH into the general circulation and the gonads 
produce estrogen and progesterone. The gonads, in response to FSH and LH, also produce inhibin and activin 
proteins. Activin enhances FSH biosynthesis and secretion, and participates in the regulation of menstrual cycle. 
Inhibin down regulates FSH synthesis and inhibits FSH secretion.  
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The regulatory endocrine loop between these organs is called the hypothalamic-pituitary-
gonadal (HPG) axis. One important function of the hypothalamus is to release Gonadotropin-
Releasing Hormone (GnRH), which binds to specific receptors on the gonadotrope cells within 
the anterior pituitary.  The gonadotropes induce the synthesis and release of gonadotropins, 
Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH), into the systemic blood 
circulation. Both FSH and LH are heterodimeric glycoproteins; the alpha subunits of both FSH 
and LH are composed of 92 amino acids (AA) while the β subunits vary.  FSH has a β subunit of 
111 AA (FSH β), which promotes its specific biologic action and is responsible for interaction 
with the FSH-receptor whereas LH has a β subunit of 120 AA (LH β) that confers its biologic 
action and is responsible for the specificity of the interaction with the LH receptor. After FSH 
and LH reach the ovary, they influence follicular maturation, ovulation, and corpus luteum 
formation through binding to their corresponding receptors expressed on the surface of target 
cells. Additionally, GCs of the ovary produce peptide-hormones such as inhibin and activin that 
are involved in ovarian hormone synthesis regulation (Drummond et al., 2012). Inhibin is 
composed of two partially homologous disulfide linked subunits; α and βA or βB thus creating 
inhibin A and B. Activin is made up of a dimer of disulfide-linked β subunits A or B creating 
activin A, B, and/or AB. Activins promote differentiation and proliferation of GCs and 
expression of FSH receptors in normal ovaries (Risbridger et al., 2001). Inhibin acts primarily to 
inhibit the secretion of FSH by the anterior pituitary gland. The relationship between inhibin and 
FSH represents a typical negative feedback mechanism since the major action of FSH is to 
stimulate the formation and function of GCs (Drummond et al., 2012). 
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1.1.2 Folliculogenesis 
The maturation process of an ovarian follicle is called folliculogenesis. During follicular 
development, the GCs surrounding the oocyte proliferate and form several layers to nuture the 
the developing oocyte and serve the endocrine function of the ovary. TCs are arranged in layers 
that surround the follicular BM and engage in paracrine signalling with the GCs of the follicle. 
The process of follicular maturation begins when the single layer of flattened GCs surrounding 
the oocyte change into a layer of cuboidal GCs (Verlhac et al., 2010; Figure 1.3). The plasma 
membrane of an oocyte in a primary follicle is surrounded by a glycoprotein membrane known 
as zona pellucida (ZP).  After development of the primary follicle, the GCs continue to 
proliferate and stay connected by tight junctions to form a protective barrier around the oocyte 
(Baerwald et al., 2012). The follicle develops into a secondary follicle when another layer of 
GCs is present outside of the ZP membrane (Verlhac et al., 2010). The fluid filled patches 
enlarge in secondary follicles to form an antral space in which the oocyte and some GCs migrate 
to one side of the follicular cavity (Verlhac et al., 2010).  At this stage the follicle is called a pre-
ovulatory follicle. Thereafter, connective tissue surrounding the GCs differentiates, forming a 
layer of TCs. As the follicle matures, it moves closer to the ovarian surface in preparation for 
ovulation. The GCs that surround the oocyte during ovulation are called cumulus cells and those 
remaining behind mural cells. The mural population undergoes luteinisation post ovulation, 
developing into the corpus luteum, which acts as a temporary endocrine gland secreting estrogen 
and progesterone to support the earliest steps of gestation (Baerwald et al., 2012). 
17 
 
Figure 1.3 Ovarian folliculogenesis 
The maturation of the ovarian follicle begins with the recruitment of non-growing primordial follicles. The GCs of 
primordial follicles change from a flat (follicular cells) to a cuboidal structure (basal lamina), the follicle is 
considered a primary follicle. The plasma membrane of an oocyte in a primary follicle is surrounded by a 
glycoprotein membrane known as zona pellucida (ZP).  The formation of zona pellucida membrane begins at early 
unilaminar primary follicle stage. At multilaminar stage, multiple layers of GCs and TCs proliferate surrounding the 
oocyte. The TCs are divided into two layers, the theca interna and the theca externa. In response to follicle-
stimulating hormone, follicular fluid accumulates in the antrum forming antral or vesticular follicle. After cavitation, 
the mature (preovulatory or graafian) follicle develops a polarity and populations of granulosa cells of the tertiary 
follicle undergo differentiation into four distinct subtypes: corona radiata, surrounding the zona 
pellucida; membrana, interior to the basal lamina (not shown in the figure); periantral, adjacent to the antrum (not 
shown in the figure) and cumulus oophorous, which connects the membrana and corona radiata granulosa cells 
together. Copyright © 2010 by The McGraw-Hill Companies, Inc, printed with permission, Appendix D (b). 
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The first phases of follicular development are controlled by groups of growth factors, including 
Transforming Growth Factor β family members (TGF-β; Myers et al., 2010). Activin and Inhibin 
are subunits which form dimeric proteins that are members of the TGF-β superfamily of growth 
and differentiation factors (O'Shea, 1981). Under the regulation of LH, TCs synthesize 
androgens, but cannot convert them into estrogen without the help of Cytochrome P450, Family 
19, Subfamily A Polypeptide 1 (CYP19A1 or aromatase; see Figure 1.4). Similarly, GCs under 
the action of FSH (also by LH at the late stage) synthesize progesterone, although they are 
unable to convert it to androgen due to lack of the necessary converting enzymes. Thus, GCs and 
TCs work collaboratively to synthesize androgens into estrogen. This collaboration starts when 
TCs convert cholesterol into androstenedione, which is then transported into the GCs and 
converted into estrogen. Besides this obligatory role of androgens as estrogen precursors in 
steroidogenesis, very little is known about their direct involvement in the female body. Vendola 
et al. in 1999 used female monkeys to investigate the interactions between FSH and androgens in 
follicular development through in situ hybridization. Vendola et al. proved that androgens 
promote follicular growth and estrogen biosynthesis indirectly, by amplifying the effects of FSH. 
Additionally, Cárdenas et al. in 2007 examined the expression of the androgen receptor (Ar) and 
FSH receptor (FSHR) in late developing follicles in pigs and concluded that androgens could 
directly promote follicle growth (Cárdenas et al., 2007). The Androgen- Receptor Knockout 
(ARKO) mice have significant reproductive defects and reduced fertility suggesting that 
androgen signaling is important for normal female reproductive health.  Sen et al. (2014) used 
GC-specific ARKO mouse model to demonstrate that androgens regulate follicular development 
and female fertility by reducing rates of follicular atresia while simultaneously promoting 
preantral follicle growth and development. However, the specific mechanisms by which 
19 
  
 
Figure 1.4  Interactions between GC and TC in the follicle 
The pre-ovulatory follicle produces estrogen through a paracrine interaction between TC and GC. Two critical steps 
in estrogen formation are the first entry of cholesterol into the TC which is converted to pregnenolone by Cyclic 
Adenosine MonoPhosphate (cAMP) and cytochrome P450 superfamily of family 11, subfamily A, polypeptide 1 
(CYP11A1). cAMP stimulates protein kinase A family of enzymes which leads to increased concentrations of 
cholesterol in the TCs.  Pregnenolone is then converted to androstenedione through multiple conversion reactions 
(multiple arrows) which is then transported into GCs. The second critical step occurs in GCs which is the conversion 
of androstenedione to Estrone by Cytochrome P450, family 19, subfamily A, polypeptide 1 (CYP19A1). Estrone is 
then converted to 17β-estradiol (E2) catalyzed by hydroxysteroid (17- β) dehydrogenase 1 (17β-HSD1) and diffused 
into vasculature. 
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androgens mediate female fertility remain unclear and the roles for androgenic signalling through 
the Ar receptor have not been examined specifically during the distinct phases of embryonic 
follicle assembly and cyclic follicular maturation in the post-pubertal ovary. 
Hirshfield was one of the first reproductive biologists to suggest the ovarian follicle 
complement could be divided into two categories based on their growth characteristics.  
Hirshfield et al. investigated the patterns of ovarian cell proliferation during the earliest stages of 
folliculogenesis in rats and concluded that the cortical primordial follicles are activated gradually 
to provide mature ova over the entire course of animal’s reproductive life, while the medullary 
follicles had a shorter span of existence with different proliferation kinetics (Hirshﬁeld et al., 
1995). A recent report by Zheng et al. using fluorescent transgene tracing methods in the mouse 
supported Hirshfield’s findings, with convincing evidence there are two distinct waves of 
primordial follicle assembly that have different developmental dynamics (Zheng et al., 2014).  
Generally, the most up-to-date model suggests the first wave of follicles to mature in the rodent 
ovary are the primordial follicles that reside in the medulla; these follicles are synchronously 
activated to provide mature eggs until approximately 3 months of age, they contribute to the 
onset of puberty and the establishment of cyclic HPG axis signalling, but they are less likely to 
contribute to fertility (Zheng et al., 2014).  The cortical primordial follicles, on the other hand, 
are formed from the recruited supporting cells in the cortical region of postnatal ovaries and 
contribute to ovulation and fertility post-puberty. Rodent models have been instrumental for our 
understanding of the major genetic and endocrine factors that influence mammalian ovarian 
development and function, but there is always the potential for species-specific differences.  In 
humans, for instance, ovulation of one oocyte is most common, while in multi-ovulatory species 
(mice, rats, cats, dogs), several oocytes are ovulated from each ovary, indicating different criteria 
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or thresholds for dominant follicle selection leading to full maturation and ovulation.  The 
establishment of the two-wave theory of follicle development in rodent species opens the door 
for  the identification of molecular markers to further explore the unique properties of each wave, 
and to confirm the two-wave model of follicle recruitment in human ovaries. 
1.1.3 Ovarian Development and the Maintenance of Female Gonad Specification  
The complex process of ovarian development starts with differentiation and specification 
of Primordial Germ Cells (PGCs), the precursors to germ cells, in the early embryo (McGraw-
Hill Companies, Inc. 2010). PGCs are cells that migrate to the bilateral genital ridges, adopt a 
sex-specific gamete fate under appropriate signals and subsequently orchestrate the somatic cell 
organization in the embryonic gonad.  The differentiation and development of PGCs is crucial 
for assuring normal fertility of the individual and the correct transmission of the genome to the 
next generation. As such, the steps of female and male gonad specification remain active areas of 
reproductive research.  Mice and humans have very similar gonad development pathways, which 
when combined with the reproductive and engineering potential of mice, makes them an 
excellent embryological model to study gonad specification or pathology (Quinn et al., 1998). 
In the early weeks of embryogenesis in humans, the embryonic disc undergoes a process 
of folding and PGCs are passively incorporated into the embryo together with the yolk sac wall. 
PGCs then migrate through the dorsal mesentery during early gastrulation to reach the 
developing gonads, the genital ridges, where they colonize and are rapidly surrounded by cords 
of somatic cells. Sexually undifferentiated mammalian embryos can develop into either female 
or male; this stage is called bi-potential or an indifferent stage, in which the appearance of the 
gonad is essentially the same in the two sexes (Gilbert, 2003). In humans, this indifferent stage is 
from 4 to 7 weeks (wks) of gestation. At the time of gonad colonization, Chr XY PGCs express 
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the Sex-determining region Y (Sry) protein, which triggers differentiation of the gonad towards 
testis fate through its target gene, the Sex-determining region Y-box 9 (Sox9) transcription factor 
(Figure 1.5). In contrast, Chr XX PGCs differentiate through an active process regulated by 
Wingless-type MMTV integration site family member 4 (Wnt4) and R-spondin 1 (Rspo1), which 
up-regulate the expression of β-catenin (Ctnnb1). Another female-sex-determining factor is 
Forkhead Box L2 (Foxl2), which is expressed as a nuclear protein in the granulosa cells of the 
embryonic and adult mouse and human ovary (Lima et al., 2012). The Wnt4/Rspo1 and Foxl2 
signaling pathways act in a complementary manner to promote ovarian development and 
maintain somatic cell identity in the female ovary through suppression of the Sox9 gene (Nef et 
al., 2009). FOXL2 mRNA expression was demonstrated by Duffin et al. to be between 8 and 19 
wks of gestation in the human fetal ovary (Duffin et al., 2009). Foxl2 protein expression in mice, 
however, begins at embryonic day (E) 12.5 in pre-granulosa somatic cells (Rafa, 2009) and is 
persistent through the reproductive lifespan. Evidence from human syndromes and other 
mammals has confirmed these pathways are not only important for the initial ovarian 
specification, but also for maintenance of female somatic cell identity and reproductive function. 
For instance, Foxl2 mutations are involved in Chr XX sex reversal in goats and depletion of 
ovarian follicles in mice and humans (Garcia-Ortiz et al., 2009). Ablation of the Foxl2 gene 
causes partial secondary sex reversal in mice and partial loss of FOXL2 function leads premature 
ovarian failure in humans (OMIM® and Nef et al., 2009).  The concept that sex specification 
requires specific signals for maintenance as well as establishment represented a change of 
thinking for the reproductive biology community; it also raised the possibility that a signaling 
imbalance could lead to a potentially tumorgenic phenotype, as one outcome of uncontrolled 
transdifferentiation.  
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Figure 1.5 Sex determination in the bipotential mammalian gonad 
The embryo with Chr XX genotype develops ovaries through Wnt4 (Wingless-type MMTV integration site family, 
member 4) and RSPO1 (R-spondin 1) stabilization of β-catenin which prevents the SRY induced expression of 
SOX9 and testis formation.  The differentiation of ovarian somatic cells is actively maintained by FOXL2 (Forkhead 
box L2) while suppressing SOX9. β-catenin stabilized by WNT4 and RSPO1 signaling suppresses SOX9 expression 
in female gonads. (Adapted from Piprek, 2009) 
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1.2 Ovarian Cancer  
In Canada, approximately 2,600 diagnoses of ovarian cancer are recorded annually, 
representing 2.9 %, or the eighth most common cause, of all new cancers in Canadian women 
(Canadian Cancer Statistics 2014).  Even more disturbing, ovarian cancer ranks as the fifth 
leading cause (4.7 %) of cancer-related deaths in women. Ovarian cancer is considered to be the 
most serious of all gynecological cancers since the majority of women with ovarian cancer are 
not diagnosed until the disease is very advanced and has metastasized; this is because symptoms 
usually do not become apparent until the tumor compresses or invades adjacent structures, 
ascites develops, or metastases become clinically evident. The prognosis of ovarian cancer 
remains very poor with 5-year survival rate of only 45 % (Erickson et al., 2013). Since ovarian 
cancer has been treated as one disease for decades, and that has led to no improvements in 
mortality, the most promising way continuing to battle ovarian cancer is to consider 
improvements in molecular genetic diagnoses, to identify the subtypes of ovarian cancer and 
treat them as distinct diseases using targeted therapies. 
 Ovarian cancer has three major subclasses based on cell populations in the ovary: 
epithelial, germ cell, and sex cord-stromal. Approximately 90 to 95 % of ovarian tumors 
diagnosed in women have an epithelial origin (Serov et al., 1973 and Tavassoli et al., 2003). 
Epithelial ovarian tumors are further grouped into five histological types: serous, mucinous, 
endometrioid, clear cell and transitional cell tumors (Brenner tumors). Serous epithelial 
carcinomas of the ovaries are the most common type, making up about two thirds of the cases 
diagnosed in women. Epithelial ovarian cancers were all thought to originate from epithelial cells 
that cover the ovaries, but more recent research has shown that a high percentage of serous 
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epithelial tumors have migrated from primary cancers of the fallopian tube epithelium (Kuhn et 
al., 2013 and Kurman et.al. 2010). 
Sex cord-stromal cell tumors (SCST) are the second most common form of ovarian 
cancer, accounting for approximately 5-10 % of all cases in women (Leung et al., 2004). This 
class of ovarian cancer encompasses tumors that may originate in the GCs, TCs, or a mixed 
population of stromal cells that are endocrinologically active; therefore, SCST ovarian cancers 
are often associated with abnormal production of sex steroid hormones, leading to clinical 
symptoms of precocious puberty in pre-pubertal girls, or excessive uterine bleeding and/or 
virilisation in post-pubertal women (Young et al., 1984). The most common types of SCSTs are 
GC tumors, TC tumors (Thecomas) and Sertoli-Leydig cell tumors, wherein somatic cells of the 
female ovary take on the characteristics of Sertoli-Leydig cells, the somatic cell counterpart of 
the testis.  Germ cell tumors are the rarest form of ovarian cancer, affecting approximately 1 % 
of women (Leung et al., 2004). As a consequence of their rarity, SCSTs and germ cell tumors are 
less well understood than epithelial ovarian cancers, in terms of their genetic or environmental 
etiology.  In contrast, epithelial ovarian cancer investigations have been spurred on by their 
association with heritable cancer syndromes and the identification of susceptibility genes and 
pathways useful for cancer subclassifications and targeted therapy development. 
A family history is a risk factor for ovarian cancer; such that if a woman has two or more 
close relatives (mother, sister or daughter) with ovarian cancer, her risk to develop ovarian 
cancer is increased (Lynch et al., 2009). There are three hereditary syndromes known to 
predispose a woman to epithelial ovarian cancer.  Two are named as Hereditary Breast-Ovarian 
Cancer (HBOC) syndromes, as a result of mutations in the tumor suppressor genes Breast 
Cancer 1, Early Onset (BRCA1) and Breast Cancer 2, Early Onset (BRCA2), accounting for 
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approximately 90 % of ovarian cancer diagnoses due to a hereditary syndrome (Buller et al., 
2002 and Lynch et al., 2009).  Both BRCA1 and BRCA2 proteins play a role in DNA double 
strand break repair, such that deleterious mutations in these factors contribute to cancer risk as a 
result of acquired DNA damage (O’Donovan and Livingston, 2010).   Female patients with 
Lynch Syndrome also exhibit increased risk for epithelial ovarian cancer, along with other cancer 
sites such as the colonic epithelium. Lynch syndrome is associated with mutations in genes of the 
DNA mismatch repair pathway, including: MutL homolog 1 (MLH1), MutS protein Homolog 2 
(MSH2), MutS Homolog 6 (MSH6), PostMeiotic Segregation increased 2 (PMS2) or Epithelial 
Cell Adhesion Molecule (EPCAM) genes. Defective DNA mismatch repair results in 
microsatellite instability (MSI), which is a useful diagnostic indicator.  Mutations in BRCA1, 
BRCA2 and other tumor suppressor genes predisposes women primarily to epithelial ovarian 
cancer, but not to other classes of ovarian cancer, suggesting different pathways are important for 
sex cord-stromal and germ cell tumor initation (Lynch et al., 2009) 
1.2.1 Granulosa Cell Tumors of the Ovary 
Sex cord-stromal GC tumors are broadly classified into two subtypes: Juvenile-type GC 
tumors (JGCTs) that occur in children or young women, and Adult-type GC tumors (AGCTs) 
that occur in peri- and postmenopausal women. AGCTs have histological proliferation of GCs 
which are often with a stromal component of fibroblasts, theca or luteinized cells (Tavassoli et 
al., 2003 and Wheater et al., 1979). AGCTs may recur up to 40 years after diagnosis (Ud Din et 
al., 2014 and Rebstock et al., 2014). This recurrence feature of AGCTs is not fully understood, 
but is a significant cause of late mortality. 
In 2009, high throughput sequencing analysis led to the identification of a common, 
somatic mutation (c.402C>G) in the FOXL2 gene that is present in almost all morphologically 
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identified human AGCTs but not JGCTs (Shah et al., 2009 and Köbel et al., 2009). The FOXL2 
mutation changes a highly conserved cysteine residue to a tryptophan (p.C134W), implicating a 
key loss of protein function, although the mechanism is not yet fully elucidated (Kim et al., 
2011). There are several hypotheses under investigation to explain the consistent association of 
this unique mutation in FOXL2 with AGCT development. Fleming et al. (2011) deduced that 
mutant FOXL2 protein increases transcription of the target gene aromatase (CYP19A1) but with 
a reduced capacity to induce apoptosis, thereby compromising GC death (Fleming et al., 2011). 
Mutation in FOXL2 gene causes the GCs to lose the ability to modulate cell cycle which results 
in decreased apoptosis in GCs (Benayoun et al., 2011 and Kim et al., 2011). 
JGCTs are the least common form of GC tumor, accounting for approximately 5 % of all 
the GCT diagnoses. Relative to AGCTs, the tumor cells of JGCTs have a high proliferation rate, 
a moderate-to-high degree of cellular atypia but are also hormonally active (Tavassoli et al., 
2003). Patients frequently have elevated levels of androgen or E2, leading to symptoms of 
virilisation or precocious puberty, respectively, with a concomitant decrease in circulating 
gonadotropins (Leyva-Carmona et al., 2009). Analysis of a cohort of 125 JGCTs showed that 44 
% of the cases occurred in the first decade of life, 34 % in the second, 18 % in the third, and only 
3 % after age 30 years (Young et al., 1984). The occurrence of JGCTs in infants and young girls 
in the absence of the somatic FOXL2 mutation suggests that JGCTs have a different genetic or 
environmental etiology compared with AGCTs. 
As a cancer of children and young adults, there is a strong rationale to search for JGCT 
susceptibility genes; however, the relative rarity of JGCTs has hindered human genetic linkage 
studies. In rodents, SCSTs are the most common spontaneous ovarian neoplasms (Greenacre, 
2004 and Thayer et al., 2007). GC tumors are observed in advanced aged (12-24 months) female 
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rodents, near the end of the reproductive life, akin to human AGCTs (Tavassoli, et al., 2003 and 
Beamer et al., 1985).  Beamer et al. reported one non-engineered, inbred mouse strain called 
SWR that exhibits spontaneous development of juvenile-onset GCT (Beamer et al., 1985). 
Therefore, the SWR mouse model has presented a unique opportunity for researchers to study 
genetic and endocrine mechanisms related to initiation and support of tumor growth that are 
applicable to human JGCTs.  
1.2.2 The SWR Mouse Model of GC Tumorigenesis 
Beamer et al. (1985) first described GCTs that appeared spontaneously in a proportion (≤ 
1 %) of young females of the SWR inbred strain (Figure 1.6). The same group confirmed that 
manipulation of the endocrine environment increased trait penetrance, such that 3 wk old SWR 
inbred females or recombinant inbred strain females derived from SWR both exhibited 
significantly increased GCT incidence (approximately 20 %), with dehydroepiandrosterone 
(DHEA) or testosterone exposure (Beamer et al., 1988; Beamer et al., 1993). This elevated GCT 
incidence was deemed sufficient to investigate the biology of the spontaneous GCTs and perform 
genetic analysis for the GC tumor susceptibility loci (Beamer et al., 1988). 
In young SWR female mice, GCT initiation takes place at puberty, age 3-4 weeks, and by 
8-10 weeks the majority of females that were destined to develop GCTs had done so, while 
unaffected females retained normal fertility through adulthood (Beamer et al., in 1985). The GC 
tumors that develop in this mouse model have striking similarities to human JGCTs (Fox, 1985). 
In both species, GC tumors occur spontaneously and at a young age in the presence of normal 
ovarian follicles; furthermore, they display similar histopathology, are associated with disturbed 
endocrine activity and have malignant properties (Beamer et al., 1988).  
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Figure 1.6  Normal and bilateral early-onset GC tumors derived from SWR female mouse 
(a)  Normal ovaries with uterus attached, taken from an SWR-derived female mouse at 8 wks of age (b) Isolated 
bilateral GC tumors with uterus attached, taken from an SWR-derived female mouse at 8 wks of age.  At 8 wks, 
GCTs are large (~10 mm3), easily visible, and highly vascularized (Used with permission from Dr. Dorward’s 
Laboratory, 2012). 
  
Normal ovaries Ovaries with GC tumors 
Uteruses 
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Figure 1.7 Steroid biosynthesis pathway 
Schematic diagram of the steroid biosynthetic pathways leading to androgen production that takes place in the TCs 
and GCs in the ovaries. In humans, the main pathway to androgen production is through conversion of 17-
hydroxypregnenolone to dehydroepiandrosterone (DHEA) rather than through conversion of 17-
hydroxyprogesterone to androstenedione. Subsequent testosterone biosynthesis can occur through conversion of 
DHEA to androstenedione (by 3β-hydroxysteroid dehydrogenase type 2), followed by the actions of 17β-
hydroxysteroid dehydrogenase type 3 to generate T, or via the intermediate metabolite androstenediol.  
 
The SWR female mice present a very unique and valuable heritable GC tumor 
susceptibility phenotype compared to other inbred or engineered mouse models currently 
available to study GC tumorigenesis. One of the most distinct and unusual phenotypes of SWR 
mice is that GC tumors spontaneously develop without any genetic manipulation. Beamer et al. 
hypothesized there must be one or a group of low penetrance GCT susceptibility (Gct) genes 
controlling the initiation and development of GCTs. Another unique phenotype of SWR mice is 
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that the GCT initiation is restricted to puberty, suggesting that Gct susceptibility genes have only 
a very short window to influence GC fate and initiate tumorigenesis (Beamer et al., 1988).  
Beamer and Tennent postulated, at the time of puberty in SWR female mice, that follicular 
maturation occurs abnormally in the first cohort of maturing follicles, leading to follicular 
breakdown and uncontrolled GC proliferation, instead of follicular atresia typically observed for 
the first wave of follicles post-puberty. However, follicular atresia in general does not correlate 
with GC tumor susceptibility in SWR females, since ongoing follicular atresia that occurs during 
the reproductive cycles of adulthood does not trigger GC tumorigenesis (Dorward et al., 2003). 
The SWR model indicates there is a discrete developmental window of JGCT susceptibility, with 
tumor initiation risk limited to the peri-pubertal stage. In combination with the evidence for two 
distinct follicle populations in the mammalian ovary, it is a reasonable hypothesis to suggest that 
the earliest, medullary follicle cohort contributes to JGCT susceptibility in SWR female mice. 
The pattern of diminishing GCT susceptibility with post-pubertal age in human cohorts of JGCT 
cases mirrors what is observed in the SWR strain, indicating that GC tumor susceptibility genes 
identified in SWR mice may provide a unique opportunity to investigate human JGCT etiology 
at the molecular level 
1.2.2.1 Genetics of GCT susceptibility in the SWR strain 
Genetic mapping studies (Beamer et al., 1988, Tennent et al., 1993, and Dorward et al., 
2013) designed to correlate genotype with phenotype have clearly demonstrated that GC tumor 
susceptibility is a polygenic and heritable trait in SWR mice, involving multiple autosomal and 
Chr X-linked loci (Table 1.1.). Three independent GC tumor susceptibility loci - Gct1 on Chr 4, 
Gct4 and Gct6 on Chr X – have a major influence over GCT susceptibility in SWR female mice, 
and so were investigated further using congenic strains that isolate the independent regions for 
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the purpose of high resolution genetic mapping and assignment of specific functions to the 
various Gct alleles.   
1.2.2.2 Gct1: The driver mutation for GC tumorigenesis 
A locus named Gct1 on distal mouse Chr 4 derived from the SWR genome was strongly 
associated with GC tumor initiation in three independent mapping crosses (Beamer et al., 1988; 
Beamer et al., 1998; Dorward et al., 2005). Consequently, the SWR allele at Gct1 (Gct1SW) was 
deemed necessary for susceptibility to GC tumor initiation in SWR mice and is considered to be 
the driver mutation for the JGCT phenotype (Beamer et al., 1988b; Beamer et al., 1988a; 
Beamer et al,. 1993; Dorward et al., 2005). The mapping studies revealed that the Gct1SW locus 
had semi-dominant activity, with required inheritance of at least one copy to confer GCT 
susceptibility in young female mice, and therefore fitting with the description of an oncogenic 
locus (Beamer et al., 1998). The Gct1SW locus also exhibits a distinct endocrine interaction with 
the androgenic metabolite dehydroepiandrosterone (DHEA), implying the genetic determinant 
within the Gct1SW locus is more likely to initiate the GC tumorigenic program in the presence of 
DHEA (Beamer et al., 1988b). The Gct1SW locus is unique in this regard, since JGCTs do not 
appear when young female mice of other inbred strains (Figure 1.8) - C57BL/6J (C57) or 
Castaneus/Ei (CAST) - are similarly treated with DHEA at puberty (Table 1.1; Beamer et al., 
1998, Dorward et al., 2005 and Smith et al., 2013). 
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Table 1.1 Chromosomal location and DNA markers for Gct loci identified in multiple mapping studies 
 
 
 
 
 
 
* Chromosomal positions were obtained through the Ensembl website (GRCm38; Ensembl Genome Browser release 75, Flicek et al., 2014). 
¹ Beamer W.G. et al., 1988. Cancer Research 48:2788-2792. 
2 Beamer W.G. et al., 1998. Cancer Research 58:3694-3699. 
3 Dorward A.M., et al., 2003 Cancer Research 63:8197-8202.  
4 Dorward A.M., et al., 2005 Cancer Research 65:1259-1264.  
5 Dorward A.M., et al., 2013. Epigenetics 8:184–191. 
6 Smith K.N., et al., 2013. Mammalian Genome. 24: 63-71. 
Gct locus Chr * Position (Mbp) 
Associated  
DNA Marker 
Strain used for mapping Gct allele activity 
Gct11,2,4,6 4 145,057 D4Mit232 SWR, SJL, CAST GC tumor permissive 
Gct21 12 46.113 D12Mit172 SWR, SJL GC tumor permissive 
Gct31 15 64.537 D15Mit133 SWR, SJL GC tumor permissive 
Gct41,2 X 99.231 DXMit96 SWR, SJL, CAST GC tumor permissive 
Gct51 9 115.121 D9Mit17 SWR, SJL GC tumor permissive 
Gct63,5 X 137.618 DXamd14 SWR, SJL, CAST GC tumor suppressor 
Gct74 1 78.206 D1Mit215 SWR, SJL, CAST GC tumor permissive 
Gct84 2 166.394 D2Mit145 SWR, SJL, CAST GC tumor permissive 
Gct94 13 111.900 D13Mit292 SWR, SJL, CAST GC tumor permissive 
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Figure 1.8 Family tree of 102 inbred strains based on SNP analysis  
Ancestral relationships between 102 inbred mouse strains based on SNP genotyping. The indicated (boxed) strains 
were crossed with SWR female mice to generate heterozygous F1 generation female offspring that were treated with 
DHEA at puberty.  Strains highlighted with a blue box (CAST/EiJ and C57BL/6J) rendered the F1 females resistant 
to GCT initiation, while the other strains highlighted in green were permissive for GCT initiation. Adapted and 
reprinted with Permission from Cold Spring Harbor Laboratory Press: Appendix D (b). 
Blue: GC tumor suppressive strain. Green: GC tumor permissive strain. 
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Given the prominent role of Gct1SW to drive the JGCT phenotype, the Gct1 locus was 
selected for independent locus mapping by a congenic strain development strategy, beginning 
with the transfer of a large genomic segment from the GCT-resistant CAST (allelic designation 
“CA”) (Figure 1.8) strain through 10 backcross generations onto the SWR strain. The result of 
congenic mapping was complete suppression of GCT susceptibility when homozygous Gct1CA 
alleles displaced homozygous Gct1SW alleles, even in the presence of DHEA (Smith et al., 2013). 
The generation of subcongenic strains carrying smaller, overlapping segments of the donor 
CAST segment resolved the Gct1 interval to 1.31 Mbp on mouse Chr 4 (Smith et al., 2013). A 
focussed investigation for Gct1 gene candidates is underway by a doctoral trainee in the Dorward 
lab, with the potential for national collaborative translation of Gct1 gene candidates identified in 
the mouse model to human JGCT cases. 
1.2.2.3 Gct4: A modifier of GCT susceptibility 
Females of the SWR inbred strain are homozygous for the Gct1SW driver mutation, but 
the penetrance of spontaneous GC tumor susceptibility without exogenous hormonal intervention 
is surprisingly low, historically recorded as < 1 % (Beamer et al., 1985).  Early-onset GCTs were 
first observed in female offspring (F1 generation) of a breeding cross between SWR females and 
SJL (allelic designation “J”) inbred strain males for a different experimental purpose (personal 
communication with A. Dorward).  Reciprocal crosses between SWR and SJL strains 
subsequently led to the identification of a modifier locus for spontaneous GCT susceptibility 
named Gct4 on Chr X, based on the GCT stimulation activity of the Gct4J allele (Beamer et 
al., 1998). The phenotypic penetrance of spontaneous GCT incidence is increased from 1 % to 
about 20 % in SWR.SJL-X congenic females that carry homozygous Gct1SW alleles along with 
Gct4J alleles on Chr X.  Given the significant influence of the Gct4 locus to spontaneous GCT 
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initiation, locus mapping was undertaken for Gct4 with an inbred strain (CAST) that is more 
distantly related to SWR than the SJL strain, offering greater mapping resolution (Figure 1.8).  
Following SWR.CAST-X congenic strain development, it was determined that the Gct4CA allele 
had a similar influence to Gct4J, increasing spontaneous GCT initiation in the absence of 
androgenic support, whereas increased concentrations of circulating androgen (T or DHEA) was 
necessary to render GCT penetrance in SWR females equal to the SWR.JL-X or SWR.CAST-X 
females. Thus, Gct4SW was considered a low penetrance allele (1 %) whereas Gct4CA and Gct4J 
support moderate penetrance (20 %) (Dorward et al., 2013). The genotype-phenotype association 
for the modifier locus mapped to the same region of Chr X in SWR.SJL-X and SWR.CAST-X 
congenic lines, inclusive of the Androgen receptor (Ar) gene. Overall, the genetic and functional 
evidence was strong for the role of androgen signaling during GCT initiation.   
An unexpected but consistent observation was made during the mapping crosses and 
congenic line development, that paternal inheritance of Gct4J or Gct4CA alleles had the same 
effect to support increased GCT incidence as the homozygous condition, but this was not true for 
maternal inheritance (Dorward et al., 2013). Although the epigenetic mechanism for the parent 
of origin bias is not yet explained, the fact that the paternal Chr X had a dominant influence on 
trait penetrance greatly accelerated the genetic mapping of X-linked Gct4 using a recombinant 
Chr X, paternal progeny test. Males carrying an SWR autosomal complement but with unique 
combinations of SWR and CAST segments on Chr X were mated to SWR dams and cohorts of 
their female offspring examined for “low penetrance” or “moderate penetrance” rates of 
spontaneous GCT development. As a result of this investigation, there are three complementary 
lines of evidence that the Androgen receptor (Ar) gene shares identity with Gct4: 1) the 26 Mbp 
mapping resolution of the male progeny test placed the Gct4 locus around the Ar gene on central 
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Chr X (Dorward et al., 2003), 2) in terms of endocrinology, SWR females have increased GCT 
incidence in the presence of Testosterone (T) ligand for the Ar gene, which is distinct from the 
interaction of DHEA with the Chr 4 autosomal locus, and 3) although there are no mutations in 
the eight protein coding exons of the Ar gene that correlate with “low penetrance” vs “moderate 
penetrance” outcomes, quantitative gene expression analysis revealed significantly reduced 
expression of the Ar gene in SWR female ovaries relative to SWR-SJL-X congenic female 
ovaries that exhibit higher spontaneous GCT incidence, even without exogenous testosterone 
exposure (Dorward et al., 2003; Dorward et al., 2013). The weight of evidence for the Ar gene as 
a candidate modifier of GCT susceptibility in the SWR model, combined with knowledge that 
the Ar protein plays a regulatory role in ovarian follicle maturation in the reproductive lifespan 
of the mouse (Sen et al., 2014) was sufficient to support the investigation of a conditional knock-
out strategy for the Ar gene in the pre-pubertal GCs of SWR females. The goal of this ongoing 
research is to determine the contribution of Ar-mediated signalling to GCT susceptibility in the 
SWR model, and to identify the target of DHEA action at the Gct1 locus in the absence of Ar. 
1.2.2.4 Parent-of-Origin Effects 
In the current era of genetics, it is understood that the mammalian genome is not 
expressed equally between the sexes, with mechanisms in place that create mild or extreme 
examples of parent-of-origin expression bias.  Genomic imprinting is an example of extreme 
expression bias, whereby non-coding RNA and chromatin modifications ensure certain genes are 
expressed in a strict parent-of-origin-specific manner. These epigenetic processes set the imprints 
at the earliest stages of embryonic development and are maintained through mitotic cell divisions 
in all somatic cells of an adult organism (Merzouk et al., 2014). Appropriate imprinting of 
certain genes is important for normal development, with severe consequences when genomic 
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imprints are defective, causing broad-spectrum abnormalities such as Angelman syndrome and 
Prader–Willi syndrome (Cassidy et al., 201).  An entire copy of Chr X is subject to epigenetic 
silencing in mammalian females in a process termed X-inactivation, to achieve dosage 
compensation with Chr XY males.  Which Chr X to silence is generally thought to be a random 
choice in the soma of the embryo, although X-inactivation itself can be imprinted (as for the 
extraembryonic tissues) or biased towards one parental Chr X copy (Merzouk, et al., 2014). As 
yet, it is uncertain what epigenetic mechanism drives the paternal effect for X-linked alleles that 
increase GC tumor susceptibility in the SWR model, although biased X-inactivation or allele-
specific expression bias for candidate genes in the GC populations of the ovarian follicles are 
reasonable hypotheses to be explored.   
1.2.2.5 Gct6: A suppressor of GCT initiation  
The strong paternal effect of the Chr X-linked Gct4J and Gct4CA alleles to increase the 
spontaneous incidence of JGCTs in SWR-derived congenic female mice created a new research 
opportunity with the incidental finding of another Chr X allele that could functionally suppress 
GCT initation.  Identification of a Gct suppressor locus arose by chance following the creation of 
the SWR.CAST-X congenic strain, which was originally developed to fine map the Gct4 locus in 
the central region of mouse Chr X.  Since the creation of congenic strains is labor intensive, 
costly and takes a relatively long time to complete, mouse geneticists are ultra-conservative at 
the outset, transferring large genomic segments from the donor strains to establish congenic 
founders’ lines that don't “miss” the genetic locus of interest. In the case of the founder 
SWR.CAST-X congenic line, the CAST donor segment included 73.511 Mbp of Chr X, from 
DXMit109 at 69.675 Mbp, to DXMit35 at 143.186 Mbp, well beyond 98.1 Mbp, the physical 
location of the Ar gene (Dorward et al., 2003). The SWR.CAST-X congenic line underwent 10 
39 
generations of backcrossing to the SWR host strain, achieving 99 % return of SWR genome, 
with the exception of the CAST donor segment (Lee M. Silver, 2001). The goal for the congenic 
strain was to investigate the location and activity of the X-linked Gct4 locus independently from 
other Gct loci; therefore, the SWR.CAST-X line was confirmed to have the GCT driver Gct1SW 
alleles reconstituted.  Despite the presence of homozygous Gct1SW, SWR.CAST-X females were 
found to be completely resistant to GCT initiation (Dorward et al., 2003; Dorward et al., 2013), 
even in the presence of androgenic (DHEA or T) steroid stimulus (Table 1.2). A new locus 
named Gct6 was hypothesized to exist within the CAST donor segment that serves a tumor 
suppressor role in the androgen-sensitive JGCT mouse model. 
Once the GCT suppressor phenotype was confirmed in homozygous SWR.CAST-X 
females, a reciprocal mating test was run with SWR inbred strain partners, to determine if the 
paternal parent-of-origin effect applied to the GCT suppressor activity of Gct6CA locus. The test 
was positive for dominant paternal activity of Gct6CA; therefore, the Gct6 locus was mapped 
using the same paternal Chr X progeny test strategy as for the Gct4 locus (Table 1.2). Males 
from the SWR.CAST-X congenic strain that carried the Gct4CA locus to support 20 % 
spontaneous GCT incidence, but with different combinations of permissive SWR genome and 
the suppressive CAST genome on distal Chr X near the Gct6 locus were mated to SWR dams. 
Cohorts of their F1 daughter offspring were subsequently examined for spontaneous GCT 
incidence at 8 wks of age. This proved to be an effective strategy, since it was relatively easy to 
measure phenotype differences in the daughter offspring when comparing GCT resistant females 
(0 % incidence) with cohorts that exhibited 20 % GCT incidence. The mapping strategy resolved 
the Gct6 locus to a 1.019 Mbp interval on distal Chr X (Dr. Dorward lab, 2013), between the 
markers DXamd11 at 136.762 Mbp and DXamd17 at   
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Table 1.2 GC tumor incidence with DHEA treatment in female progeny 
GCT phenotype 
Permissive Suppressive 
Strain Cross 
(Maternal x Paternal) 
DHEA-induced  
GCT incidence % (n)* 
Strain Cross 
(Maternal x Paternal) 
DHEA-induced  
GCT incidence % (n)◊ 
SWR x SWR (inbred) 24.3 (107) SWR x C57 (F1) 0.0 (155)◊ 
SWR x SJL/Bm (F1) 14.0 (107) 
SWR x SWR.CAST-X 
(F1 congenic, Gct6CA) 
0.0 (58)◊ 
SWR x BUB/BnJ (F1) 13.7 (95) 
SWR x PL/J (F1) 10.0 (80) 
SWR x  SWR.C57-X 
(F1 congenic, Gct6C57) 
Unknown 
SWR x ST/bJ (F1) 21.9 (32) 
 
* Dietary DHEA 
◊ Capsule DHEA 
Strains are grouped according to GC tumor phenotype; permissive or suppressive for DHEA-induced GC tumorigenesis. Mice were necropsied at 8 weeks of age 
and examined for GC tumors. This project will investigate whether SWR x SWR.C57-X (F1 congenic) line belongs under the suppressive category (Adapted 
from Petkov et al., 2004, Beamer et al., 1988 and Tennent et al., 1993).  
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137.053 Mbp (Figure 1.9). The mapped interval includes 20 annotated candidate genes along 
with other genetic determinants that were candidates for Gct6 identity (Figure 1.10 and Table 
1.3). Gct6CA action is fundamentally different from Gct6SW or Gct6J alleles contributed by the 
SWR or SJL strains, respectively, since it blocks the action of both DHEA and testosterone in 
female mice that carry confirmed, autosomal susceptibility alleles for GCT initiation. This 
suggests that the Gct6CA allele interferes with the oncogenic mechanism triggered by the DHEA-
responsive Gct1SW locus on Chr 4 (Dorward et al., 2013), and/or suppresses androgenic signaling 
through Gct4 (Ar). To verify the mechanism of tumor suppressor action in the GC population, 
research efforts are now focussed on the identity of Gct6. 
The Gct6 allele from the CAST strain gave the first indication that an independent X-
linked locus had GCT suppressor activity, implying biologically-relevant allelic differences exist 
between the Gct6 locus of CAST and the other strains involved in the search for GCT 
susceptibility genes.  Since the activity of all the Gct loci are heritable across mouse generations, 
Gct1, Gct4 and Gct6 variation is expected in the germline DNA of the strains of interest. For 
Gct6, DNA sequence comparisons between the SWR and CAST genome would be a starting 
point for the identification of unique Gct6CA alleles; however, the CAST strain is highly 
divergent from SWR and most common lab strains of mice, as illustrated by the ancestral 
relationship of inbred strains (Figure 1.8) (Petkov et al., 2004). Rather than systematic candidate 
gene investigations for unique Gct6CA alleles, it is feasible to capture all the genetic variation 
across the Gct6 locus at one time, incorporating both protein coding, regulatory and intronic 
regions. With the refined Gct6 interval already mapped to 1.019 Mbps, an objective sequencing 
strategy was implemented that combined whole Gct6 locus capture of CAST and SWR strain 
DNA with a Next Generation Sequencing (NGS) approach, recognizing that a very high number 
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Figure 1.9 Haplotype map of the Gct6 interval on distal mouse Chr X 
The CAST strain donates a GC tumor resistant allele at Gct6, which greatly contrasts with Gct6SW and Gct6J alleles 
that are permissive for GC tumorigenesis (~20 %) when tested on an SWR autosomal inbred background in the 
presence of a strong Gct4CA allele.  Based on the allelic difference between Gct6J and Gct6CA, and the known 
paternal parent-of-origin effect contributed by the paternal Chr X, males carrying unique recombination of SJL 
(white boxes) and CAST genomic segments (black boxes) were derived from the SWR.CAST-X congenic strain, 
mated to SWR females, and the spontaneous GC tumor incidence of F1 female offspring was recorded.  This map 
represents the genotype of only six of the most informative recombinant males tested in the region of Gct6, placing 
Gct6 between two custom SSLP DNA markers (DXamd20 and DXamd14) that are 1.019 Mbp apart on distal Chr X.  
The map does not show the Gct4 locus on Chr X, which was fixed as a strong, permissive allele (Gct4CA) for all 
tested males. Ratios at the base of each unique male genotype represent the total number of female mice with 
spontaneous GC tumors over the total number of females examined at 8 wks of age (Used with permission from Dr. 
Dorward’s Laboratory, 2012). 
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Figure 1.10  Gct6 locus Ensembl screen shot comparison between mouse and human. 
Gct6 locus identified by red box both in mouse and human. Ensembl Genome Browser release 75 (Flicek et al., 2014) was used to capture both screen shots. 
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Table 1.3  Predicted genes within the Gct6 interval 
 
Gene 
Symbol 
Position (38 
Ensembl) 
Ensembl ID 
(ENSMUSG000000) 
Description Function Gene Type 
Predicted     
number of 
Transcripts 
Tceal3  
X: 136590842-
136668378 
44550 
Transcription Elongation 
factor A (SII)-like 3 
Transcriptional regulation protein-coding 7 
7SK 
X: 136704178-
136704470 
88864 ncRNA --- Misc RNA 1 
Tceal1 
X:136707982-
136711478 
49536 
Transcription Elongation 
Factor A (SII)-Like 1 
Transcriptional regulation protein-coding 1 
Morf4l2 
X:136732942-
136743690 
31422 Mortality Factor 4 Like 2 Transcriptional regulation protein-coding 16 
BC065397 
X:136741858-
136743143 
72960 cDNA BC065397 --- protein-coding 1 
BC065397 
X:136741858-
136743143 
87368 cDNA BC065397 --- 
processed 
transcript 
7 
Glra4 
X:136757674-
136780141 
18595 
Glycine Receptor Subunit 
Alpha-4 
Inhibition of neuronal firing Protein-coding 4 
Plp1 
X:136822671-
136839733 
31425 
Proteo-lipid protein 
(myelin) 1 
Formation or maintenance 
myelin 
Protein-coding 5 
Rab9b 
X:136858147-
136868755 
43463 
Rab9b member RAS 
oncogene family 
Protein transportation between 
the endosomes and the trans 
Golgi network 
Protein-coding 1 
H2bfm 
X:136927325-
136928373 
48155 
H2B histone family, 
member M 
Core component of nucleosome Protein-coding 
1 
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Misc RNA: miscellaneous RNA 
ncRNA: non-cording RNA 
 
Gene 
Symbol 
 
Position (38 
Ensembl) 
Ensembl ID 
(ENSMUSG000000) 
Description Function Gene Type 
Predicted    
number of 
Transcripts 
Tmsb15l 
X:136954988-
136976869 
72955 Thymosin  β  15b like --- protein-coding 1 
Tmsb15b2 
X:136955265-
136975497 
89996 Thymosin  β 15B2 Organization of the cytoskeleton Protein-coding 2 
Tmsb15b1 
X:136974022-
136976874 
89768 Thymosin  β 15b1 --- protein-coding 1 
Slc25a53 
X: 136981116-
137038302 
44348 
Mitochondrial Carrier 
Triple Repeat 6 
Trans-membrane transport protein-coding 14 
Zcchc18 
X:136993155-
136998472 
31428 
Zinc finger CCHC domain 
containing 18 
--- protein-coding 3 
Fam199x 
X:137049594-
137082503 
42595 
Family with sequence 
similarity 199 X-linked 
--- protein-coding 1 
SNORA17 
X:137093612-
137093726 
89191 
snoRNA - small nucleolar 
RNA, H/ACA box 17 
--- ncRNA --- 
Esx1 
X:137115397-
137122083 
44348 
Extraembryonic 
Spermatogenesis 
homeobox 1 
Placental development and 
spermatogenesis. 
protein-coding 3 
SNORA63 
X:137150815-
137150933 
65095 
snoRNA, Small Nucleolar 
RNA, H/ACA Box 63 
--- ncRNA 1 
Il1rapl2 
X:137570608-
138846946 
59203 
Interleukin1 receptor 
accessory protein-like 2 
Associated with X-linked non-
syndromic mental retardation. 
protein-coding 3 
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of variants would be predicted for the polymorphic CAST genome vs the C57 reference or SWR 
genome. It was also appreciated that identification of another strain besides CAST that confers 
GCT suppressor activity from the distal Chr X region would greatly facilitate the search for Gct6 
identity based on the hypothesis that a common allele would co-segregate with GCT suppressor 
activity. If the hypotheses is true, it would support an informatics filtering strategy to eliminate 
DNA sequence variations in the CAST strain that are not relevant to the GCT phenotype. 
Beamer et al. (1988-b) screened for DHEA-induced GCT incidence in F1 hybrid female 
offspring of SWR dams mated to males from 9 different inbred strains: AKR/J, MA/MyJ, 
RIIIS/J, RF/J, SJL/Bm, ST/bJ, BUB/BnJ, PL/J and C57BL/6J (C57). Females from these inbred 
strains do not share the trait of GCT susceptibility with the SWR strain, but the F1 offspring 
from eight of the crosses (cohort size 32 to 155 females) exhibited GCT incidences from 1 % to 
22 %, following inheritance of only one maternal copy of Gct1SW, one copy of Chr X from the 
paternal strain and complete heterozygosity on the remaining autosomes (Table 1.3). It was 
fortuitous that the crosses were designed for paternal Chr X inheritance, since the experiment 
established that Gct6AKR, Gct6MA, Gct6RIIIS, Gct6RF, Gct6ST Gct6BUB and Gct6PL were GCT 
permissive alleles, and confirmed the permissive nature of the Gct6J allele from the SJL strain 
(Beamer et al., 1985). The paternal strain that stood out as a potentially harbouring a GCT 
suppressor locus was C57, with 0 GCTs recorded of 155 (SWR x C57) F1 females treated with 
DHEA from puberty until 10 wks of age (Beamer et al. 1988, Table 1.3). This data suggested 
that CAST and C57 could share the GCT suppressor allele at the Gct6 locus, although it cannot 
be firmly concluded that X-linked Gct6 is responsible for GCT suppression in this cross with this 
experimental design. Since the F1 females examined were heterozygous for SWR and C57 loci 
across the entire genome, it was possible a different suppressor locus was at work. The definitive 
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strategy to deconstruct polygenic traits in mouse models is to isolate the locus of interest in a 
congenic strain and test genotype/phenotype associations. We therefore proposed to construct a 
SWR.C57-X congenic line that carries the Gct6C57 locus based on positional information learned 
from the SWR.CAST-X mapping panel. With the Gct6C57 locus isolated, SWR.C57-X females 
would be investigated for their GCT susceptibility upon treatment with DHEA. If the SWR.C57-
X strain females are GCT-resistant, there would be a strong rationale to search for common 
genetic determinants and perhaps common alleles between CAST and C57 genomes across the 
Gct6 locus.  
1.3 NGS Technology and Prior Collaborative Work 
Genetic analysis has been transformed in the past decade with technological advances to 
sequence whole genomes consecutively with high-throughput, NGS platforms. NGS is a nucleic 
acid sequencing technology that simultaneously determines the sequence of many thousands or 
millions of short templates in a single sequencing run.  Although the chemistry of current NGS 
platforms differ, the mass acquisition of sequencing information makes use of the reference 
genome scaffolds for many species to realign short sequencing reads for the detection of rare 
variant sequences in whole exomes, genomes or transcriptomes, in a qualitative and a 
statistically quantitative manner (Brown, 2013).  To apply NGS methodology in the search for 
Gct6 identity, a research collaboration was established with The Jackson Laboratory (TJL; Dr. 
Laura Reinholdt) to avail of the Illumina platform sequencing core facility at TJL and their 
informatics pipeline for mutation discovery in the mouse.   
Since Gct6 was already mapped to high resolution with phenotype-driven mapping protocols, 
a targeted sequencing approach was deemed the most efficient step to isolate the entire Gct6 
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locus of the SWR inbred strain and SWR.CAST-X congenic line DNA, prior to NGS sequencing 
(Simon et al., 2012). Gct6 locus enrichment was accomplished using a SureSelect DNA capture 
microarray (Agilent Technologies Inc.), customized to capture and enrich the SWR inbred strain 
and SWR.CAST-X congenic strain DNA with a generous interval (2.1 Mbp) across the mapped 
1.019 Mbp Gct6 locus. The array was designed with a 3 bp offset and 60 bp probe length, 
masking simple repeat regions, but representing all possible coding, regulatory and intronic 
regions within the locus.  Enriched, captured DNA for the Gct6 interval was subsequently 
fragmented into 100 bp lengths followed by sequencing on an Illumina HiSeq2500 using 2 x 100 
paired end sequencing protocol.  The fragment reads were aligned to the C57 reference genome 
(Archive Ensembl release 67 - May 2012 © WTSI / EBI). Primary, secondary and tertiary NGS 
analysis was performed at TJL according to their standard protocols (Simon et al., 2012).  
Individual variant reports comparing SWR to C57 reference genome and CAST to C57 reference 
genome were provided to our lab group for follow-up analysis of variants in Gct6 candidate 
alleles.   
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 2.0 Hypotheses and Research Objectives 
Hypotheses:  
The C57 strain harbours a GCT suppressor allele within the mapped Gct6 locus interval 
on Chr X.  
Genetic variants in common between the CAST and the C57 strain across the Gct6 locus 
are candidate tumor suppressor alleles that abrogate androgen-sensitive GCT initiation in SWR 
mice. 
Research Objectives: 
1) To develop a six-generation SWR.C57-X congenic strain that transfers C57 genome to 
the mapped Gct6 region on mouse Chr X, and to test the GCT susceptibility of female 
offspring that paternally inherit the Gct657 locus in the presence of DHEA.  
 
2) To perform informatics analysis and sequence confirmation for genetic variants identified 
by a whole-Gct6 locus capture and NGS technique for the Gct6SW GCT-permissive locus 
vs the Gct6CA –suppressor locus, relative to the C57 strain reference genome. 
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 3.0 Materials and Methods 
3.1 Animal Housing 
Mice were housed at the central animal care facility in the Health Sciences Centre at 
Memorial University of Newfoundland. All animal care protocols were approved by the 
Institutional Animal Care Committee, in accordance with Canadian Council on Animal Care 
guidelines.  Mice were given Laboratory (autoclavable) Rodent Diet 5010 food (27.5 % protein, 
13.5 % fat, 59 % carbohydrate; OM Nutrition International, Richmond, IN) with sterile water ad 
libitum, and were housed under a 12:12 hour (h) light/dark cycle.  Mice were weaned at 20-23 
day of age and housed in groups of 2 to 5 animals per 27.94 cm L x 17.78 cm W x 12.7 cm H 
rodent cages containing Bed-O-Cobs® corn-cob bedding material (The Andersons, Maumee, 
OH).  
 
3.2 Development of the SWR.C57-X Congenic Strains 
An outcross mating between SWR and C57 inbred strains was performed to create N1 generation 
progeny that are fully heterozygous at every autosomal and Chr X locus (N1F1). The N1F1 
progeny were selectively bred for 5 additional backcross generations (N) to SWR inbred strain 
mates, followed by an intercross generation (N6F2) to generate 2 homozygous SWR.C57-X 
congenic lines (N6F3).   SWR.C57-X Line 1 harboured a 65 Mbp continuous segment of C57 
strain genome that introduced both Gct6C57 and Gct4C57 loci, delimited by simple sequence 
length polymorphic (SSLP) markers informative to distinguish SWR vs C57 background 
(DXMit119, DXMit96, DXMit117, DXamd22 and DXamd14 (Table 3.1).  SWR.C57-X Line 2 
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carried a smaller 38 Mbp segment of C57 genome that introduced only the Gct6C57 locus, 
delimited by DXMit117, DXamd22 and DXamd14 SSLP DNA markers (Table 3.1). At each 
backcross generation, only those offspring who inherited both Gct4C57 plus Gct6C57 (Line 1) or 
just Gct6C57 (Line 2) alleles were selected for the next round of backcrossing. At the N6 
generation, approximately 95 % SWR genome was reconstituted while 5 % was from the C57 
donor strain, including the desired region on Chr X that contains the Gct4 and Gct6 loci (Silver, 
1995; Figure 3.1). To evaluate the phenotype of Gct6C57 independently from the driver mutation 
Gct1SW, all the selected N6 offspring chosen as founder mating pairs for the SWR.C57-X 
congenic strain were confirmed to be homozygous for the Gct1SW allele using the D4Mit232 
SSLP marker genotyping by Simple SSLP.  
 
3.2.1 Tail Tip Collection and DNA Extraction 
Approximately 1-2 mm of tissue was removed from the tip of the tail using scissors upon 
necropsy or during weaning. Tail tips were placed in 1.5 mL microcentrifuge tubes with 500 µL 
of 50 mM sodium hydroxide (BDH Inc., Toronto, ON), and heated at 95 ºC for 10 min. After the 
addition of 50 µL of 1 M Tris-HCL pH 8.0 (Sigma-Aldrich Inc., St. Louis, MO; Fisher 
Scientific, Fair Lawn, NJ), the samples were centrifuged at 10,000 x g for 10 min, and the 
supernatant transferred to new 1.5 mL microcentrifuge tubes. DNA samples were stored at -20 
ºC prior to genotyping protocols. 
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3.2.2 Polymerase Chain Reaction (PCR) 
Genomic DNA extracted from mice tails was amplified using a MasterTaq PCR Kit (5 PRIME 
Inc., Gaithersburg, MD). The following reagents were combined in a 0.2 mL PCR tube (Bio-Rad 
Laboratories, Hercules CA): 4.35 µL of ultrapure distilled water (Invitrogen, Carlsbad CA), 2 µL 
of 5X TaqMaster PCR Enhancer pre-heated to 65 ºC, 1 µL of 10X Reaction Buffer, 0.2 µL of 10 
mM deoxynucleotide triphosphates-dNTPs (Invitrogen, Carlsbad, CA), 0.05 µL of Taq DNA 
polymerase (5 Units/µL), 0.2 µL of 10 µM forward and reverse primers (see Table 3.1; 
Integrated DNA Technologies, Coralville, IA) and 2.0 µL of DNA template. Ten microliter 
reactions were amplified in a VeritiTM 96-well thermal cycler (Applied Biosystems) using the 
following PCR protocol: 97 ºC for 30 s; 39 cycles of 94 ºC for 15 s, 55 ºC for 30 second, 72 ºC 
for 30 s; 72 ºC for 10 min; 4 ºC hold. 
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Table 3.1 PCR primer sequences for SSLP DNA markers at Gct1, Gct4 and Gct6 loci. 
 
Region 
Marker 
Symbol 
Forward primer sequence (3' > 5') Reverse primer sequence (5' >3') Chr: Positions * 
Gct1 D4Mit232 GCGTCACCACACTGCTCTT ACTCAGAGTCCCCTGGCC 4: 145057739-145058007 
Gct4 DXMit119 CTT TAA CCA TAA TAA TGG CCT TGC GGG TTC TGT GAT CGC AAG TT X: 72410246-724103 
Gct4 DXMit96 CATGTCAATTGGGATCTTTGG AGGAGCAAATCCAACCTGG X: 99231474-99231566 
Gct6 DXMit117 GTAAAACCGCACTGACTAAGCC TTCGCCTCTATCTTACTCTGGC X: 131288026-131288151 
Gct6 DXamd22 CCT TCC CTC TCA CTG TGT CC AAT GCC ATG GTT TTG CTC AT X: 137088324-137088343 
Gct6 DXamd14 CCA TGT GTG ACG ACT TGA CC CCC ACT CCA AAT TAG TAC CAA CA X: 137618303-137618322 
 
DXMit primers were obtained through MGI website (Blake et al., 2014).  
DXamd primers (Custom SSLP markers) were created by Dr. Ann Dorward at Memorial University of Newfoundland. 
*data were obtained through Ensembl Genome Browser release 75 (Flicek et al., 2014). 
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Figure 3.1 Isolating Gct1SWR, Gct4C57 and Gct6C57 in a congenic strain 
A schematic representation of the relative C57 and SWR contributions at sequential generations of backcrossing. 
Gct4SW and Gct6SW are swapped with Gct4C57 and Gct6C57. By the sixth generation of backcrossing, the differential 
segment around the selected loci (Gct4 and Gct6) represent the major contribution from C57 genome.  
Black: C57; White: SWR; Red: Heterozygous.  
(Adapted from Silver, 1995) 
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3.3.1 Gel Electrophoresis 
Amplified PCR products were separated by horizontal electrophoresis through a 4 % 
high-resolution agarose gel. Bromophenol blue loading dye of 0.25 % (W/V) Bromophenol blue 
and 40.0 % (W/V) sucrose, was added to each PCR reaction of 10 µL and mixed to a final 
concentration of 1X. PCR products were resolved on 4 % agarose gels, composed of 8 gr of 
Metaphor agarose powder (Lonza, Mississauga ON) mixed with 20 mL of 10X TBE buffer (890 
mM Tris, 20 mM EDTA (pH 8) and 890 mM Boric acid) and 172 mL H2O. The gel mixture was 
boiled using a microwave for 4 min, and poured into a gel tray (HE 99X Max Horiz Sub unit 
Hoefer, Inc, San Francisco, CA). The PCR reactions and 500 ng of 100 base pair 1 Kb DNA 
ladder marker (Bio Basic Inc., Markham, ON) were loaded into individual wells. The horizontal 
gels were run in 1 X TBE buffer for 3.5 h at 110 V, after which they were stained for 30 min in a 
bath containing 50 µL of ethidium bromide solution-10 mg/ml (Sigma-Aldrich Inc., St. Louis, 
MO) diluted in 1 L of water. The SSLP PCR products were visualized using a U: Genius GelVue 
UV transilluminator (302 nm; Syngene, Frederick, MD) and scored for allele size by comparison 
to SWR, C57 and SWR.C57-X strain control DNA amplified under the same PCR conditions. 
3.4 Gct6C57 Allele Phenotyping 
Ten congenic SWR.C57-X males (5 from Line 1 and 5 from Line 2) were mated once 
more to SWR females in a paternal progeny test for the GC tumor suppressor activity of Gct6C57. 
All female offspring born (N7F1) were implanted with a subcutaneous DHEA-filled capsule at 
weaning (age 20 – 24 d) to stimulate androgen-induced GC tumorigenesis. Ultra-pure DHEA 
(Steraloids Inc., Newport, RI, USA) was packed into 1.0 cm capsules made from Silastic tubing 
(1.98-mm inner diameter 93.18-mm outer diameter; Dow Corning, Midland, MI, USA) capped 
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with glass beads (Beamer et al., 1988). Capsules were implanted subcutaneously on the back of 
mice under isoﬂurane anesthesia (Baxter Corporation, Mississauga, ON, Canada) with 
postoperative carprofen (5 mg/kg body weight) analgesic (Pﬁzer Canada, Kirkland, QC, Canada) 
and stainless steel wound closure clips. 
All heterozygous females were euthanized by CO2 gas at 8 wks and examined 
macroscopically for GC tumors with a visual inspection of both ovaries (Figure 3.2). At this age, 
GC tumors usually present as cystic or solid hemorrhagic masses of 5–10 mm in diameter and 
may be bilateral. If a unilateral or bilateral GC tumor was detected, the offspring was considered 
as one affected female for the purpose of tumor incidence calculations. A sample size (n) of 
minimum 50 individual females born from each congenic paternal cohort was determined based 
on statistical power calculations using an estimated DHEA-induced GC tumor incidence of 20 % 
in inbred SWR females recorded both historically and following transfer to the HSC from 
another institute, relative to a tumor-resistant phenotype (0 % incidence) in SWR.CAST-X 
congenic lines (Beamer et al. 1988 and Smith, 2012).  
3.4.1 Reciprocal Test of SWR.C57-X  
A reciprocal test was done by mating SWR.C57-X Gct6C57 heterozygote females with 
SWR males and treating their offspring with a DHEA capsule to prove that paternal inheritance 
of Gct6 is enough to induce the tumor suppressive phenotype; the incidence of GC tumors were 
recorded. 
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Figure 3.2 Sample collection paradigm for GC tumor incidence of congenic SWR.C57-X 
daughters implanted with DHEA capsules. 
Congenic daughters SWR.C57-X were implanted with DHEA capsules at 3 weeks of age. They were necropsied at 8 
wks and checked for the presence of GC tumors.  
 
 
3.4.2 Homozygote Test of Gct6C57 SWR.C57-X  
A homozygote line of Gct6C57 was created through mating SWR.C57-X Gct6C57 females 
with SWR.C57-X Gct6C57 males and treating their offspring with a DHEA capsule. The GC 
tumor incidence was examined and recorded in the same manner as the SWR.C57-X congenic 
line. This experiment was an additional layer of proof to indicate the tumor suppressive 
phenotype of the paternal inheritance of Gct6. 
3.5 Statistical Analysis 
Sample size was initially calculated based on a power calculation, with a predetermined 
tumor incidence rate of 18 % in the SWR strain used in this study that were treated with DHEA. 
Study power and significance level were selected to be 80 % and 0.05 respectively. For a zero 
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rate of incidence in the resistive group, the power calculations show a sample size of (at least) 49 
is required for the selected power and significance level. Fisher’s exact test (Preacher et al., 
2001) was then used to determine the p-values in order to confirm significance requirements 
have been met. The GC tumor incidence of both Line 1 and Line 2 N7F1 female cohorts was 
individually compared to the SWR inbred line incidence using the Chi-squared analysis for 
proportions, with a chosen signiﬁcance level of P < 0.05. Statistical analyses was performed with 
GraphPad Prism ver. 5.00 Software (San Diego, CA, USA). 
3.6 Histology 
Representative ovaries with unique genotypes and phenotypes were taken at necropsy 
(approximately 8 wks of age) for histological analysis. Two ovaries with GC tumors, one from a 
SWR.C57-X Gct6C57 congenic mouse and one from an SWR mouse, were prepared for 
histological analysis. Additionally, normal ovaries were taken from 2 individual SWR.C57-X 
Gct6C57 congenic mice. The ovaries were carefully dissected under the microscope and 
immediately placed in 4 % paraformaldehyde in phosphate buffer (PFA) pH 7.4 for 5-6 h. After 
fixation in PFA, the ovaries were stored in 70 % ethanol overnight. The samples were then sent 
to Histology department of the Faculty of Medicine for paraffin embedding, sectioning, slide 
mounting and hematoxylin and eosin staining. The histology slides were observed under Leica 
DM-IRE2 inverted microscope (Leica Microsystems, Richmond Hill, ON, Canada) attached to a 
Retiga Exi CCD camera (QImaging, Burnaby, BC, Canada). Openlab Image Analysis software 
(Version 5.5; Improvision, Inc., Lexington, MA, USA).  
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3.6.1 NGS Variants List for Gct6 
The list of variants identified for the Gct6 locus were represented in an excel table format 
with the following headings: Chromosome, Position, Reference_Base, Consensus_Base, SNP 
quality, Depth, Allele frequency (non-reference allele), Mapping quality, Exon, Exon ID, Strant, 
Intron, Intergenic, Function class, Transcript(s), Gene symbol, Strand, Ensembl version  (for 
sample data, see Appendix E). The first filtering step for the variant list was to exclude variants 
based on their reported allele frequency (AF). From this dataset, an AF of 1.0 indicated a 
homozygous variant while AF of 0.5 indicated heterozygosity. The DNA samples sent to The 
Jackson Laboratory were isolated from homozygous congenic or inbred strain animals, so we 
hypothesized that all variants with AF less than 1.0 indicated a technical error during the 
sequence assembly steps, and so these variants were not considered further. 
The remaining variants with AF of 1.0 were reviewed as to whether they were in 
common between SWR and CAST genome vs the C57 reference genome (Figure 3.3). The 
common variants were excluded from further consideration given the rationale that Gct6SW and 
Gct6CA are hypothesized to be genotypically different, based on the distinct GC tumor permissive 
vs. suppressive phenotypes conferred by two strain alleles. The remaining variants were 
prioritized by their location relative to annotated features of the locus, labelled as intronic, 
intergenic, or exonic, with exonic variants given higher priority if they influenced the protein 
coding sequence vs the untranslated regions of genes. Finally, exonic coding variants were 
filtered to prioritize non-synonymous over synonymous variants.  The non-synonymous variants 
were labeled as high priority for sequence validation and consideration for Gct6 identity (Figure 
3.3). 
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Figure 3.3  NGS filtering steps diagram 
The NGS variants list included all the differences between C57 and each tested strain (CAST vs C57 and SWR vs 
C57). The variants that reside within Gct6 locus were isolated for both, then the common variants between CAST 
and SWR according to their bp nucleotide positions were removed from the data set (Filter 1). Only variants with 
different alleles from CAST were kept (Filter 2) for further analysis. The remaining variants were then further 
broken down into Intronic, Exonic and Intergenic categories as well as synonymous and non-synonymous. The 
priority was given to non-synonymous coding exonic variants.  
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3.7 Sanger sequencing preparation  
3.7.1 PCR Amplification  
DNA was extracted from tail tips of SWR, SWR.C57-X and SWR.CAST-X mice as 
previously described (Section 3.3.1). DNA from additional GCT permissive strains (PL/J, 
BUB/BnJ, SJL/Bm and ST/bJ) was ordered from The Jackson Laboratory. The following 
reagents were combined in a 0.2 mL PCR tubes: 15.2 µL of distilled water, 7.0 µL of 5X 
TaqMaster PCR Enhancer preheated to 65 ºC, 3.5 µL of 10X Reaction Buffer, 0.7 µL of 10 mM 
dNTPs (Invitrogen, Carlsbad, CA), 0.175 µL of Taq DNA polymerase (5 PRIME, Inc. MD, 
USA) kept on ice, 0.7 µL of 10 µM forward and reverse primers and 7.0 µL of DNA template or 
ultrapure distilled H2O (negative control; Invitrogen, Carlsbad CA). The 35 µL PCR reactions 
were amplified in a VeritiTM 96-well thermal cycler with primers flanking the nonsynonymous 
variants in BC065397, Slc25a53, Esx1 and Tmsb15l (Table 3.2) under the following conditions: 
5 min at 95 ºC; 6 cycle of 15 s at 95 ºC, 30 s at 68 ºC decreasing 1 ºC per cycle, 68 ºC for 1 min; 
35 cycle of 15 s at 95 ºC, 62 ºC for 30 s, 68 ºC for 1 min; 72 ºC for 10 min; 4 ºC hold.  
3.7.1.1 Gel electrophoresis 
PCR products (10 µL) were run on a 1 % agarose gel, followed by horizontal gel 
electrophoresis and visualization of the products. The 50 mL gel prepared in 1 x TBE solution 
contained 0.5 g agarose (Sigma, St. Louis MO), boiled for 2 min to dissolve the agarose, after 
which 2 µL of 10 mg/mL ethidium bromide was added (Sigma-Aldrich Inc., St. Louis, MO). The 
gels were cast, loaded, electrophoresed for 30 min at 110 V and PCR products visualized as per 
the protocol for SSLP genotyping (Section 2.2). 
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3.7.2 DNA Purification from PCR Products  
PCR products were purified using a QIAquick® PCR purification Kit-250 (Qiagen Inc., 
Mississauga, ON) as per the manufacturer’s protocol. Five volumes of binding buffer was added 
to one volume of PCR product. If the PCR products’ color indicator was orange or violet 
meaning the solution is basic, therefore 10 µL of 3 M sodium acetate (pH 5.0) was added to 
bring the solution pH close to 7.0, before transfer to a 2 mL QIAquick column and centrifuged 
for 1 min at 13000 rpm. After centrifugation, the flow through was discarded. Seven hundred and 
fifty µL of wash buffer was added to the QIAquick columns and the centrifugation step was 
repeated and flow through was discarded. The centrifuge and wash steps were repeated once 
more. The filter column was transferred to a new 1.5 mL micro-centrifugation tube, 50 µL of EB 
(10 mM Tris·Cl, pH 8.5) was added to the center of each column, incubated for 5 min and 
centrifuged at 13000 rpm for 1 min. The flow through samples containing the eluted DNA 
samples is preserved so that the purity of the samples can be assessed. 
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Table 3.2 Sanger sequencing primers used to amplify amplicons from protein coding transcripts within Gct6. 
 
        
Genes 
Symbol 
Forward primer sequence (5' > 3') Reverse primer sequence (5' > 3') Products length (bp) 
BC065397 
GGATGCCTGGATGCTTTGGA 
GGGCATAAGGGAGATTCGCA 722 AGGCGAGGTCCCTCATTTTG * 
TGCTAGTATCTAAAGGAAAGGGCT* 
      
 Esx1 GATGCAGTCAAATGCCACCC  ACCCCAGGAAAAAGCCACTC 626 
    
  
Tmsb15l  CAG GAA GCA CTT ACA TAT CCC CA 
CGT CTC CAC AGC CAG TTT CT  
513 
ACGT CTC CAC AGC CAG TTTC ◊ 
      
 Slc25a53 TGAGGGATGCGGGAACTAGA   GCAAACCAGCCTCGGTATCT 315 
 
 
Primers were designed using NCBI primer blast tool (Geer et al., 2010).  
* indicates primers used only for Sanger sequencing.  
◊ Primer used only to amplify and sequence CAST.   
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3.7.3 Quality Assessment of Purified DNA  
The quality of the purified DNA samples were assessed Thermo Scientifi NanoDrop 
1000 Spectrophotometer. The readings were viewed by ND-1000 V3.5.2 software. The ratio of 
absorbance at 260 nm and 280 nm (260/280) was used to assess the purity of DNA samples. The 
260/280 ratio of 1.8-2 was accepted as pure and a lower ratio value may indicate the presence of 
protein, Phenol or other contaminants that absorb strongly at or near 280 nm. A secondary 
measure of nucleic acid purity of ratio 260/230 values of 2-2.2 were used for the purity of 
nucleic acid.  Lower 260/230 ratio values may indicate the presence of organic contaminants 
which absorb at 230 nm in the samples. The samples with the 260/280 ratio of higher than 1.21 
and 260/230 ratio of higher than 1.41 were sent for Sanger sequencing. 
3.7.4 Sanger Sequencing  
All of the Sanger sequencing reaction were run at the Genomics and Proteomics Facility, 
Core Research and Equipment and Instrument Training Network, Memorial University of 
Newfoundland, using a BigDye® Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems 
Inc., Foster City, CA). The following reagents were combined in a 0.2 mL PCR tube: 1 µL of 5X 
Sequencing Buffer, 0.5 µL of BigDye® Terminator v3.1 Cycle Sequencing mix, 1 µL of either 
1.6 pmol/ µL forward or reverse primer, 10 ng of purified DNA template and H2O to bring the 
volume to 10 µL. A control reaction containing 1 µL of 5X Sequencing Buffer, 0.5 µL of 
BigDye® Terminator v3.1 Cycle Sequencing mix, 1 µL of -21 M13 Control Primer, 1 µL of 
pGEM® -3Zf(+) template, and 6.5 µL of distilled water was included with each sequencing run. 
PCR was performed in a GeneAmp® PCR System 9700 Thermal Cycler (Applied Biosystems 
Inc., Foster City, CA) using the following protocol: 96 ºC for 5 min, 25 cycles of 96 ºC for 10 s, 
50 ºC for 5 s, 60 ºC for 4 min; and a 4 ºC hold. The sequencing products were then purified with 
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an ethanol precipitation and subsequent ethanol wash with the addition of 2.5 µL of 125 mM 
EDTA and 65 µL of 95 % ethanol (Commercial Alcohols, Brampton, ON).  The tubes were 
vortexed, centrifuged briefly, covered in aluminium foil and stored at 4 ºC overnight. The 
following day, the tubes were centrifuged at 3,000 x g for 30 min at RT, and the supernatants 
were discarded by inverting the tubes on a paper towel and a subsequent centrifugation of the 
inverted tubes (or plates) at 200 x g for 25-35 s. DNA pellets were suspended in 150 µL of 70 % 
ethanol by vortexing and pelleted by centrifugation at 3,000 x g for 15 min. Purified cycle 
sequencing products were resuspended in 15 µL of Hi-DiTM Formamide (Applied Biosystems 
Inc., Foster City, CA), briefly vortexed and centrifuged. Purified cycle sequencing were 
denatured for 3 min at 96 ºC in a GeneAmp® PCR System 9700 Thermal Cycler (Applied 
Biosystems Inc., Foster City, CA), loaded into a cassette and sequenced in a 3130 or 3730 
Genetic Analyzer (Applied Biosystems Inc., Foster City, CA). Sanger sequencing for Slc25a53 
and Tmsb15l genes for ST/bJ, SJL/Bm, BUB/BnJ and PL/J strains done at the Genomics and 
Proteomics Facility, Core Research and Equipment and Instrument Training Network, Memorial 
University of Newfoundland. 
3.7.5 Sequence Analysis 
Sequences generated by Sanger sequencing methods were aligned for variant analyses 
using Sequencer® version 4.10.1 (Gene Codes Corporation, Ann Arbor, MI). All experimentally-
determined sequences were aligned to the C57 strain reference genome, downloaded from 
Ensembl Genome Browser release 75 (Flicek et al., 2014). 
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3.7.6  Protein Alignment across Species  
Protein sequence comparisons between species were created for the indicated high 
priority genes (Esx1, Slc25a53 and Tmsb15l) using ClustalW2 alignment program (Larkin et al., 
2007). These genes were chosen  for further investigation due to the non-synonymous variant 
reported by NGS and confirmed by Sanger sequencing resulting in AA change and truncated 
protein. The species-specific AA sequences were obtained through the orthologue database of 
Ensembl Genome Browser release 75 (Flicek et al., 2014). Two species with the highest target % 
ID were chosen from each species set (Primates, Rodents, Laurasiatheria, Sauropsida and Fish) 
for protein sequence alignment. Target % ID refers to the percentage of the sequence in the 
target specie (mouse) that matches to the query sequence (e.g. human). 
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 4.0 Results 
4.1 Phenotypic Mapping of Congenic SWR.C57-X Mice 
Two groups of 5 congenic SWR.C57-X males from Line 1 and Line 2 were chosen to enter 
the paternal progeny test designed to independently test the tumor suppressor phenotype of the 
Gct6C57 locus in the presence of the Gct1SW driver mutation for GC tumor susceptibility. The 
males were mated to SWR dams with a minimum, combined cohort of n=50 N7F1 females 
generated from each line to provide sufficient statistical power when dealing with a low 
penetrance trait. Both paternal groups carried Gct1SW and Gct6C57 alleles and one line also 
carried Gct4C57 alleles, a recognized modifier locus for GC tumor susceptibility. The haplotype 
map for Chr X of each male entered into the progeny test is shown using SSLP DNA markers 
informative for Gct4 and Gct6 loci between SWR and C57 strains (Figure 4.1). N7F1 daughter 
offspring from each mating were implanted with DHEA capsules at puberty and examined for 
GC tumors at 8 wks of age.  The GC tumor incidence was calculated as the number of females 
with GC tumors versus the total number of daughters examined, as is reported below, the locus 
haplotype for each male in Figure 4.1.  The Line 1 female offspring with homozygous Gct1SW on 
Chr 4 and paternally inherited Gct4C57 and Gct6C57 alleles on Chr X had zero incidence of GC 
tumors, even when treated with DHEA (0 of 50 examined); whereas the Line 2 N7F1 female 
offspring that carried homozygous Gct1SW on Chr 4 and paternally inherited Gct4SW and Gct6C57 
alleles on Chr X had one GC tumor incidence identified (1 of 58 examined; see Figure 4.1). 
However, the GC tumor incidence of individual N7F1 females that inherited a paternal Gct6C57 
allele in total (1/108 Line 1 and 2 combined) was significantly reduced compared to SWR inbred 
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females (9/51; Fisher’s exact test p-value = 0.00016 < 0.05, Preacher et al., 2001), but similar to 
paternal inheritance of Gct6CA suppressor allele (0/58).  
Thus both SWR.C57-X congenic lines were considered GC tumor suppressive while 
carrying the Gct6C57 allele. This proved our hypothesis that similar to the CAST strain, the C57 
strain also harbours a GC tumor suppressor allele at Gct6 locus on Chr X. Therefore, common 
genetic variants within CAST and C57 strain across the Gct6 locus are candidate tumor 
suppressor alleles that initiate androgen sensitive GC tumors in GC tumor permissive strain 
(SWR) mice. Due to the highly polymorphic characteristics of the CAST strain, the search for 
the candidate tumor suppressor variant was approached by analyzing the genetic differences 
between SWR and C57 across the Gct6 locus, to significantly reduce the number of variants to 
be investigated. An examination of GCT incidence in DHEA-treated females from the 
homozygous Gct6C57 congenic line further supports the conclusion that the Gct6C57 allele has GC 
tumor suppressor activity, since no GC tumors were observed among the 39 female mice 
examined at 8 wks age (Table 4.1). 
 
Table 4.1 GC tumor incidence of homozygote Gct6C57 SWR.C57-X line 
 
 
 
 
 
SWR.C57-X congenic 
GC tumor incidence 
treated with DHEA 
Total examined 
Gct6C57 homozygote 0 33 
Gct6C57 and  Gct4C57 homozygote 0 6 
Total 0 39 
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Figure 4.1 Haplotype map of SWR.C57-X congenic males and GC tumor incidence 
measured in their daughter offspring following pubertal treatment with DHEA. 
The N7F1 female offspring of line 1 that carried Gct1SW, Gct4C57 and Gct6C57 alleles were GC tumor suppressive as 
they had zero incidence of GC tumor after treatment with DHEA. Line 2 harbouring Gct1SW and Gct6C57 alleles had 
one incidence of GC tumor after treatment with DHEA.  
Red box: CAST; Black box: C57; White box: SWR.  
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4.2 Histology  
The ovaries collected upon necropsy at 8 wks of age were fixated for histologic analysis. 
The GC tumor witnessed in line 2 harbouring only paternally-derived Gct6C57 was identified as 
GC tumor and it resembled the GC tumor histology of SWR mice (Figure 4.2).  
4.3 Candidate Gct6 Variants Identified by Whole Locus Sequencing 
The locus capture plus NGS sequencing strategy for Gct6 identified thousands of DNA 
sequence variations distributed across the locus when SWR or CAST strain genome was aligned 
to the C57 reference genome (Appendix E). After filtering based on AF criteria, the SWR vs C57 
file contained 1151 variants while the CAST vs C57 file contained 4053 variants (Figure 4.3). 
Phenotypic mapping of congenic SWR.C57-X mice proved that Gct6C57 also behaves as a 
GC tumor suppressor; therefore, the easier strategy was to evaluate the report with fewer variants 
list (SWR vs C57) and confirm in CAST genome when warranted. Subsequently, the files were 
cross referenced for common variants between SWR and CAST genomes, which would be 
removed from further consideration based on the confirmed phenotype differences between 
Gct6SW and Gct6CA. Three variants were identified in common between CAST and SWR that 
were removed from the data set.  
The remaining 1148 variants were further filtered according to C57 and CAST alleles 
available for only the annotated variants. According to the selection criteria [(C57 = CAST) ≠ 
SWR], 402 additional variants were removed from the data set after compared to annotated SNPs 
in dbSNP databse. The remaining 746 variants were mapped out according to their gene position 
(Figure 4.4).  Five hundred sixty of the 746 variants had rs IDs and were identified as 
“reference SNPs”, 17 were categorized as “other annotated variants” as they were not given any 
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designated rs IDs and 169 were labeled as novel variants since they were not found in any of the 
online databases (dbSNP, Ensembl and Wellcome Trust Sanger Institute; see Figure 4.3). The 
746 variants were 463 intronic, 75 exonic and 208 intergenic variants. The 75 exonic variants 
were given priority and into two categories of coding (10 variants) and non-coding (65 variants). 
From the 10 exonic/coding variants, 5 were nonsynonymous variants that caused an AA change. 
These 5 nonsynonymous variants were given highest priority for further analysis and 
confirmation through Sanger sequencing (Table 4.2).  
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Figure 4.2 Histology of GCTs vs Normal ovaries. 
 
A. GC tumor from line 2 congenic SWR.C57-X N7F1 female offspring carrying Gct6C57 allele taken at 40X 
magnification. B. GC tumor from SWR mouse taken at 20X magnification. C. and D. Represent two normal ovaries 
taken from two different mice from line 2 congenic SWR.C57-X N7F1 female offspring carrying Gct6C57 allele 
taken at 20X magnification. 
  
GC tumor cells 
Normal Ovarian follicles 
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Figure 4.3 Filtering strategy for homozygous Single Nucleotide Polymorphisms (SNPs) 
between CAST vs. C57 and SWR vs. C57 reference genome across the mapped 
Gct6 locus. 
Targeted whole-locus capture of the Gct6 region (Agilent Sure-Select Array) from SWR inbred and SWR.CAST-X 
congenic DNA was processed for NGS (Illumina Hi-Seq) at The Jackson Laboratory.  Variant calls were made 
relative to the C57 reference genome for both Gct6CAST and Gct6SWR input. The CAST region (4,053 variants) was 
significantly more polymorphic than SWR (1,151 variants), such that C57 vs SWR variants were prioritized for 
analysis and subsequently compared to CAST genome. Three SNPs common between CAST and SWR were filtered 
out, leaving 1148 variants (Filter 1). The referenced portion of the 1148 were checked for CAST allele via dbSNP 
website and the variants that did not have the same allele as C57 were removed from data set (Filter 2) leaving only 
746 variants left to be categorized as intronic, exonic or intergenic SNPs and further subdivided as reference SNPs, 
"other annotated" or "novel" variants. Five nonsynonymous variants were isolated for further analysis. 
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Figure 4.4 Physical distribution and annotation of 746 SNPs identified between C57 and SWR genomes across the Gct6 locus. 
Schematic diagram of mouse Chr X (GRCm38; Ensembl Genome Browser release 75, Flicek et al., 2014). The Gct6 locus of 1.019 Mbp on distal region of Chr 
X of mouse is shown by a black rectangle. (b) The 746 NGS variants isolated from “SWR vs C57” data set are mapped out and distributed unevenly among the 
20 candidate genes of Gct6 GC tumor suppressor. The variants are further subdivided into different color-coded categories of exonic (red), intronic (orange) and 
intergenic (grey). The 5 nonsynonymous variants are shown by black arrows.    
Gct6 Locus 
Mouse Chr X Gct6 Locus: 1.019 Mbp 
(b) 
(a) 
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Table 4.2 Variant sequence validation and predicted A. A. deviations in SWR vs C57. 
rs IDs of 5 nonsynonymous variants were taken from the Ensembl website (GRCm38; Ensembl Genome Browser release 75, Flicek et 
al., 2014). All the 5 nonsynoymous NGS reported variants were confirmed by Sanger sequencing. 
Gene 
Symbol 
SNP reference ID 
Chr X position 
(Mb) 
NGS reported 
variant 
Sanger Sequence 
confirmation 
Consequence 
Slc25a53* rs29261702 137.0 C/T C/T ACC/ATC - Thr/Ile 
Tmsb15b1 rs13484019 136.9 C/T C/T CCG/CTG - Pro/Leu 
Tmsb15l rs13484019 136.9 C/T C/T CCG/CTG - Pro/Leu 
Esx1 rs240547705 137.1 T/G T/G TCC/Gcc - Ser/Ala 
BC065397 rs244048438 136.7 GTTT/GTTTGTTT GTTT/GTTTGTTT 
GTTT/GTTTGTTT - 
Phe/Leu 
 
*   Sanger sequencing Slc25a53 in SWR mice revealed the NGS reported variant and the deletion of 28 bp from two adjacent 28 bp repeats. 
 GTTT frame shift insertion bypasses stop codon and adds nine additional AA (Leu, Phe, Leu, Arg, Pro, Val, Val, Thr and Arg) before reaching a downstream 
secondary stop codon. 
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4.1 Sanger Sequencing 
4.1.1 BC065397 
The gene BC065397 is not annotated in humans; in mice, however, it is a protein-coding 
gene with only one transcript (BC065397-201 ENSMUST00000089350) that has one coding 
exon that encodes 141 AA residues (Figure 4.5 a). NGS reported an INDEL variant of 
GTTT/GTTTGTTT (rs244048438) at genomic location of 136,742,379. This INDEL causes a 
frame shift which substitutes Phe (aromatic AA) by Leu (nonpolar aliphatic AA) causes the 
original stop codon to be bypassed and add nine AA residues (Leu, Phe, Leu, Arg, Pro, Val, Val, 
Thr and Arg) before reaching a secondary stop codon. 
Sanger sequencing, BC065397, revealed that both C57 and CAST strains carry GTTT 
allele while SWR strain carries GTTTGTTT INDEL allele (Figure 4.5 b). However, the allele 
information obtained through Ensembl Genome Browser revealed that the INDEL did not co-
segregate with other GC tumor permissive strains (ST/bJ, SJL/Bm, BUB/BnJ and PL; see Table 
4.3). Therefore, BC065397 is given a low priority in our search for the Gct6 candidate gene. 
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(a) 
 
(b) 
 
Figure 4.5 Sanger sequence alignment of BC065397 gene in SWR.C57-X, CAST and SWR mice. 
(a) Schematic diagram of BC0650397 transcript (BC065397 ENSMUSG00000072960); the coding exon is shaded in red and non-coding exons are represented 
by non-shaded boxes (Ensembl Genome Browser release 75, Flicek et al., 2014). Exon 1 (black arrow) with flanking sequences was amplified and sequenced. (b) 
Sanger sequencing of BC065397 gene confirmed NGS reported variant (black box). Only SWR strain carries GTTT INDEL variant. 
Light Blue: excellent sequence quality, Medium Blue: Average sequence quality, Dark Blue: poor sequence quality, Not-shaded: Reference sequence
78 
4.1.2 Esx1 
Human Extraembryonic, Spermatogenesis, Homeobox 1 gene (ESX1) gene has one 
transcript (ESX1-001 ENST00000372588) that is a protein coding transcript of 1,495 bp 
containing sequences of four coding exons and translating 406 amino acid residues (Figure 4.6 
a); while mouse Esx1 gene has 3 protein coding transcripts. The NGS reported variant resides 
within the first transcript of Esx1 at 1,692 bp (Esx1-002; ENSMUST00000113066) that has four 
coding exons translating 314 AA residues (Figure 4.6 b). NGS showed a variant of T > G 
(rs240547705) at 137,118,653 bp position. This SNP replaces Ser (polar uncharged AA) with 
Ala (nonpolar AA) and was confirmed through Sanger sequencing (Figure 4.6 c). Esx1 has 
multiple highly conserved regions among species however this particular SNP is within less 
conserved region of the protein which suggests that this SNP is likely to cause any disease 
(Appendix A). Esx1 Sanger sequence revealed that both C57 and CAST strains carry the “T” 
allele while the SWR strain carries the “G” allele. Further analysis of the Esx1 alleles among 
other GC tumor permissive strains (ST/bJ, SJL/Bm, BUB/BnJ and PL) indicated that this allele 
does not co-segregate with all the GC tumor permissive strains (Table 4.3). Therefore, this gene 
is given low priority for the candidate gene Gct6 locus GC tumor suppressor.  
4.1.1 Tmsb15l and Tmsb15b1 
Thymosin β 15b like (Tmsb15l) and Thymosin β 15 1 (Tmsb15b1) genes are both protein-
coding genes in mice. In humans, the closest gene to Tmsb15l and Tmsb15b1 is TMSB15A which 
has one protein coding transcript (TMSB15A-001 ENST00000289373) of 685 bp with 3 coding 
areas translating 45 AA residues (Figure 4.7 a). 
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(a) 
 
(b) 
 
(c)                       
Figure 4.6 Sanger sequence alignments of Esx1 gene in SWR.C57-X, CAST and SWR 
mice. 
(a) Schematic diagram of human ESX1 protein coding transcript (ESX1-001 ENST00000372588) with 4 coding 
exons shaded in yellow and noncoding regions are represented by non-shaded boxes (Ensembl Genome Browser 
release 75, Flicek et al., 2014). (b) Schematic diagram of mouse Esx1 protein coding transcript (Esx1-002; 
ENSMUST00000113066) with sequence of 4 coding exons shaded in red and noncoding regions are represented by 
non-shaded boxes ( Ensembl Genome Browser release 75, Flicek et al., 2014). Exon 2 (black arrow) with flanking 
intronic sequences was amplified and sequenced. (c) Sanger sequence alignment of SWR.C57-X, CAST and SWR. 
NGS reported SNP T > G (C57 vs SWR) was confirmed (shown in black box). Both SWR.C57-X and CAST carry 
the “T” allele while SWR carries “G” allele. 
Light Blue: excellent sequence quality, Medium Blue: average sequence quality, Dark Blue: poor sequence quality, 
Not-shaded: Reference sequence 
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Table 4.3 Gct6 alleles associated with GC tumor- permissive or - suppressive activity. 
Strain Cross (maternal x paternal) 
DHEA-
induced GCT 
incidence 
% (n) 
Gct6 allele 
phenotype 
Slc25a53 
(-strand) 
Slc25a53 
28 bp repeat 
Deletion-Insertion 
Tmsb15l (- 
strand) 
Tmsb15b1 
(- strand) 
Esx1 
(- strand) 
BC065397 
(+ strand) 
SWR (inbred) 17.8 (51)1 Permissive T Deletion T T G GTTTGTTT 
SWR x SJL/Bm (F1) 14.0 (107)2 Permissive T Deletion T T G GTTTGTTT 
SWR x BUB/BnJ (F1) 13.7 (95)2 Permissive T Deletion T T G GTTTGTTT 
SWR x PL/J (F1) 10.0 (80)2 Permissive T Deletion T T G GTTT 
SWR x ST/bJ (F1) 21.9 (32)2 Permissive C Insertion C C T GTTTGTTT 
SWR x C57 (F1) 0.00 (155)2 Suppressive C Reference C C T GTTT 
SWR x SWR.C57-X (F1 congenic) 0.90 (108) Suppressive C Reference C C T GTTT 
SWR x SWR.CAST-X (F1 congenic) 0.00 (58)3 Suppressive C Reference C C T GTTT 
Shaded area indicates suppressive strains. 
 After AA 11 and 20 of 346 the Slc25a53 frame shift deletion and insertion add 63 and 78 additional residues before reaching their secondary stop codons, 
respectively. 
¹ Smith K.N., et al., 2013. Mammalian Genome. 24: 63-71. 
² Beamer W.G. et al., 1988. Cancer Research 48:2788-2792.    
³ Dorward A.M., et al., 2013. Epigenetics 8:184–191. 
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In mice, Tmsb15l and Tmsb15b1 are positioned on Chr X in such a way that approximately 50 % 
of their sequences overlap. Analysis of the NGS data showed a T > C SNP (rs13484019) located 
within this overlapping region. The NGS report therefore includes two records of this SNP. The 
same amino acid change occurs in both Tmsb15l and Tmsb15b1. Hence only one primer was 
used to target this region. 
Tmsb15l has only one transcript (Tmsb15l-001; ENSMUST00000127404) of 816 bp that 
has 4 exons coding for 80 AA residues (Figure 4.7 b). NGS reported T > C change at 
136,975,409 bp position that causes a substitution of Pro (a polar uncharged AA) to Leu 
(Nonpolar AA) confirmed by Sanger sequencing (Figure 4.7 c). Upon Tmsb15l protein 
comparison between species it was revealed that Tmsb15l protein carries an extra 35 AA residues 
at the N terminus of the protein that only exists in mice (Appendix B). This extra AA residues 
might serve as a signal peptide, although not clearly annotated as a signal peptide in 
BLAST/BLAT Ensembl genome browser. Tmsb15l is a highly conserved protein and therefore it 
is presumed to have an evolutionary important function (Appendix B). However, the lack of 
correlation between the alleles and the phenotyped strains reduced the priority of the variant as 
sharing identity with Gct6. 
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(a) 
 
(b) 
 
(c)              
 
Figure 4.7 Sanger sequence alignment of Tmsb15l gene in SWR.C57-X, CAST, SWR and 
the permissive and suppressive strains associated with GC tumor activity in 
mice. 
(a) Schematic diagram of TMSB15A transcript with 3 coding exons shaded in yellow and noncoding regions are 
represented by non-shaded boxes (yellow boxes; Ensembl Genome Browser release 75, Flicek et al., 2014). (b) 
Schematic diagram of Tmsb15l transcript with 4 coding exons shaded in red and noncoding regions are represented 
by non-shaded boxes (Ensembl Genome Browser release 75, Flicek et al., 2014). Exon 2 with flanking sequences 
was amplified and sequenced (black arrow). (c) Sanger sequencing of Tmsb15l gene confirmed NGS reported SNP 
(shown in black rectangle) of G > A. SWR.C57-X, CAST and ST/bJ carry the “G “allele while the SWR, SJL/Bm, 
BUB/BnJ and PL/J strains carry the “A” allele. 
Light Blue: excellent sequence quality, Medium Blue: Average sequence quality, Dark Blue: poor sequence quality, 
Not-shaded: Reference sequence 
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(b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8 Human SLC25A53 gene comparison with mouse Slc25a53 gene 
(a) Schematic diagram of human SLC25A53 transcript indicating its two coding exons (yellow boxes) exons and 
noncoding regions represented by non-shaded boxes. (b) Schematic diagram of Slc25a53 gene indicating the 7 
coding exons (yellow boxes) and noncoding regions represented by non-shaded boxes. NGS reported SNP reside 
within Exon 6 (black arrow).  
Ensembl website (GRCm38; Ensembl release 75 - Febuary 2014 © WTSI / EBI) 
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4.1.1 SLC25A53 
In humans, Solute Carrier Family 25, Member 53 (SLC25A53) also known as MCART6, is a 
protein-coding gene that has two transcripts. Only one transcript, however, is a protein coding 
transcript (SLC25A53-001 ENST00000357421); it is 6,224 bp long containing sequences of two 
coding exons which when translated produces a peptide with 307 amino acids (Figure 4.8 a). In 
mice, Slc25a53 has 14 transcripts with only five annotated as protein coding transcripts. The 
NGS data indicated -SNP in Slc25a53 gene resides in the transcript Slc25a53-001 
(ENSMUST00000113069) containing sequences of 7 coding exons and translating 346 AA 
residues (Figure 4.8 b). The PCR amplicons were checked for appropriate size before Sanger 
sequencing using agarose electrophoresis.  In the case of Slc25a53, there were amplicon size 
differences between SWR, CAST and C57.  The SWR genomic samples produced a smaller PCR 
fragment while the SWR.C57-X and SWR.CAST-X samples had the expected PCR amplicon 
size of 315 bp (Figure 4.9).  
Sanger sequencing of SLc25a53 in SWR, SWR.C57-X and CAST confirmed the NGS reported 
SNP of C > T change, causing an AA substitution of Thr (polar uncharged AA) with Ile 
(nonpolar aliphatic AA). Sanger sequencing also revealed a 28 bp fragment deletion of 2 
adjacent 28 bp repeats in SWR mice. Further analysis of Slc25a53 gene in GC tumor permissive 
strains (SJL/Bm, BUB/BnJ, PL/J and ST/bJ) showed yet another difference in PCR fragment size 
among the strains once separated by 1 % gel electrophoresis (Figure 4.10). It was observed that 
STb/J strain carries a longer amplicon than SWR.C57-X and SWR.CAST-X strains while the 
rest of the permissive strains harboured a shorter amplicon. Sanger sequencing of all the 
permissive strains revealed that the same 28 bp fragment deletion exists in SJL/Bm, BUB/BnJ 
and PL/J but not ST/BJ.  Instead, ST/bJ  Sanger sequence showed an 8 bp fragment deletion 84 
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bp upstream the Slc25a53 exon 6 (the UTR region; see Figure 4.11 a) and a 28 bp repeat 
insertion immediately after the end of the two repeat sequence in the coding region of Slc25a53 
exon 6 (Figure 4.11 b). The 8 bp deletion and 28 bp insertion in ST/bJ strain compensated for the 
slightly (20 bp) heavier ST/bJ (335 bp) band. Similarly, the 28 bp fragment deletion in SWR, 
SJL/Bm, BUB/BnJ, PL/J accounted for their lighter (-28 bp) band of 287 bp when compared to 
SWR.C57-X and SWR.CAST-X controls that has the intended 315 bp amplicon. Slc25a53 gene 
is highly conserved among species; however, the NGS reported SNP resides within a region that 
does not exists in any other species (Appendix C). Protein sequence comparison between species 
also revealed that mice have an extra 40 AA residues at the N terminus of Slc25a53 protein 
(Appendix C). These extra AA residues are thought to be a signal peptide although it is not 
specifically annotated as a signal sequence in public databases. Even though the NGS reported 
SNP did not co-segregate completely with GC tumor permissive and suppressive phenotype, it is 
evident that all the GC tumor permissive strains have some sort of deviation of either an insertion 
or a deletion thus lacking an intact Slc25a53 gene (Table 4.3). This evidence has given Slc25a53 
gene the highest priority and the best possible gene candidate for Gct6 GC tumor suppressor 
activity. 
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Figure 4.9 Slc25a53 check gel prior to Sanger sequencing 
The Slc25a53 amplicons ran for one hour at 110 V on a 1% agarose gel prior to sequencing with two independent 
DNA samples from SWR.CAST-X and SWR mice, and four independent DNA samples from congenic line 
SWR.C57-X. SWR. The 100 base pair 1 Kb DNA ladder marker was used along with Bromophenol blue loading 
dye for the horizontal gel electrophoresis analysis.  
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Figure 4.10 Slc25a53 alleles across GC tumor – suppressive and –permissive strains. 
Allele association analysis between 5 Gct6 permissive (SWR, SJL/J, PL/J, BUB/BnJ, ST/bJ) and 2 Gct6 suppressive 
(CAST, C57) strains revealed size differences across GC tumor – suppressive and –permissive strains. SWR, SJL/J, 
BUB/BnJ and PL/J strains carry the lighter Slc25a53 gene amplicon of 287 bp while the ST/bJ strain carries a 
heavier band of 335 bp. The suppressive strains (SWR.C57-X and SWR.CAST-X) carry the intended amplicon of 
315 bp fragment of Slc25a53 gene. The amplicons were ran for one hour and half at 110 V on a 1% agarose gel. The 
100 base pair 1 Kb DNA ladder marker was used along with Bromophenol blue loading dye for the horizontal gel 
electrophoresis analysis. 
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Figure 4.11 Multiple Sanger sequence alignments of Slc25a53 gene in GC tumor permissive and suppressive strains. 
(a) This figure is the upstream flank of Slc25a53 Exon 6. Sanger sequencing of ST/bJ strain revealed an 8 bp deletion located 84 bp upstream of Slc25a53 Exon 6 
UTR. (b) This figure represents the sequence within the coding region of Slc25a53 Exon 6. The NGS reported SNP C > T (C57 vs SWR) was confirmed through 
Sanger sequencing. Sanger sequencing of GC tumor permissive strains (SWR, ST/bJ, SJL/Bm, BUB/BnJ and PL) showed that all but ST/bJ carry the “T” allele. 
Ten bp downstream of the NGS reported SNP, there is a 28 bp deletion of repeat 2 in SWR, SJL/Bm, BUB/BnJ and PL/J strains. After repeat 2, there is a 28 bp 
insertion of the repeat sequence in ST/bJ. (This diagram was generated manually to best illustrate the insertion, deletion and repeats that take place in Slc25a53 
gene among GC tumor –permissive and –suppressive strains). 
Light Blue: excellent sequence quality, Medium Blue: Average sequence quality, Dark Blue: poor sequence quality, Not-shaded: Reference sequence 
(a) 
(b) 
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 5.0 Discussion  
A spontaneous, heritable GC tumor phenotype in SWR inbred female mice has revealed 
several Gct susceptibility loci influential for early tumor initiation in the presence of an 
androgenic environment: Gct1 (Beamer et al., 1988; Beamer et al. 1998; Dorward et al., 2005; 
and Smith et al., 2013), Gct4 (Beamer et al., 1988; Beamer et al. 1998) and Gct6 (Dorward et 
al., 2003 and Dorward et al., 2013). In the SWR model, paternal inheritance or biparental 
inheritance of the Gct6 locus from the CAST genome contributes a GC tumor resistant function. 
The tumor suppressor activity of the Gct6CA allele overrides the activity of the Gct4 GC tumor 
modifier locus on Chr X and the oncogenic activity of the Gct1SW alleles on Chr 4, indicating that 
the Gct6CA allele suppresses the androgen-initiated GC tumorigenic program while preserving 
the normal function of the mouse ovary.  The suppressor activity contributed by Gct6CA was 
unique when compared to all previous strains examined in breeding crosses with the SWR strain, 
suggesting a unique CAST allele within the mapped Gct6 locus was a master controller of a 
biologic pathway that influenced GC tumor susceptibility.  The only other strain examined by 
Beamer et al. that suggested equivalent tumor suppression was the C57 strain, although the 
activity was not mapped to any specific chromosome (Beamer et al., 1985). The results of this 
project have confirmed the Gct6C57 locus confers GCT suppressor activity similar to Gct6CA, 
which also provided a more powerful strategy for Gct6 variant analysis following targeted NGS 
sequencing of the locus.  
5.1 Gct6C57 allele contribution to GC tumor susceptibility 
Through the development of the six-generation SWR.C57-X homozygous congenic lines, 
the independent contribution of Gct6C57 allele to GCT resistance was tested.  Based on the 
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experimental history that paternal inheritance has a dominant influence over Chr X-linked GCT 
susceptibility loci, my experiment was initially designed as a progeny test, mating SWR dams 
with SWR.CAST-X sires who contributed a Chr X genomic segment harbouring only C57 alleles 
(Gct4C57/Gct6C57) or a combination of alleles (Gct4SW/Gct6C57)  to daughter offspring in the 
presence of SWR strain genome at all other loci (Dorward et al., 2003; Dorward et al., 2013).  
The female offspring were subsequently examined for GCT susceptibility with DHEA exposure 
beginning at puberty. Similar to the CAST genomic contribution at Gct6, we determined that 
paternal inheritance of the Gct6 locus from the C57 genome leads to a significant reduction in 
GC tumor initiation. Female mice examined from either (SWR x SWR.C57-X) cross that 
inherited a paternal Gct6C57 allele revealed only 1 confirmed unilateral GCT at necropsy of a 
total of 108 females examined from both congenic lines combined.  This proportion was 
significantly reduced compared to the expected GCT incidence of SWR inbred females treated 
with the same DHEA supplementation paradigm and sacrificed at 8 wks of age (9/51; Fisher’s 
exact test, p = 0.00016; Smith et al., 2013).  In contrast, low GCT incidence following paternal 
inheritance of Gct6C57 was similar to the suppressed GCT incidence measured following paternal 
inheritance of the Gct6CA tumor-resistance allele (Dorward et al., 2013). One alternate 
interpretation for the low GCT incidence measured in (SWR x SWR.C57-X) F1 females 
receiving DHEA treatment, was ineffective GCT stimulus by the DHEA protocol, since the 
positive control strain SWR was not simultaneously included in my experimental design.  
However, a concurrent DHEA implantation experiment ongoing in the lab using SWR inbred 
female mice, the same DHEA source and DHEA administration protocol, the same timing of 
surgical implant at puberty but a slightly earlier age at necropsy (5-6 wks as opposed to 8 wks) 
recorded 15.4 % GCT incidence: (8/52 confirmed tumors) with additional suspicious GCT 
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specimens (Ms. Kerri Smith).  The historically consistent GCT incidence rate in SWR females 
administered DHEA (Beamer et al., 1985 and Smith et al., 2013) gives strong support to my 
conclusion that low GCT incidence in (SWR x SWR.C57-X) F1 females is due to the tumor 
suppressor activity of Gct6C57 allele, not an ineffective tumor induction protocol.  Thus, the 
SWR.C57-X paternal progeny test supported the hypothesis that a common Gct6 tumor 
suppressor allele in C57 and CAST genomes is distinct from the permissive Gct6SW allele, 
leading to our hypothesis that common phenotypes are supported by a common genotype, or a 
common genetic target, between the CAST and C57 strains, which is unique from the SWR 
strain or other proven GCT-permissive strains (Dorward et al., 2013).   
The paternal dominance of the X-linked Gct6CA allele is observed though the recorded 0 
% GCT incidence of F1 females that inherit two different Gct6 alleles, the maternal permissive 
(Gct6SW) and the paternal suppressive (Gct6CA) alleles (Dorward et al., 2013). The outcome is not 
the same when heterozygous females inherit the Gct6CA allele maternally, reinforcing the 
paternal parent-of-origin effect for the GCT susceptibility loci (Dorward et al., 2013)  Such a 
reciprocal cross has not been completed with the newly developed SWR.C57-X strain, although 
the findings from the paternal progeny test described suggests a similar paternal effect to the 
SWR.CAST-X studies. The dominant paternal effect of C57-X and CAST-X congenic lines 
precludes an allele complementation test, which would have been an excellent functional test 
using our congenic resources to determine whether Gct6CA and Gct6C57 are the same alleles. An 
allele complementation test works for recessive traits or semi-dominant traits, where two 
suspected “mutant’ alleles are brought together by selective breeding to see if the trait is fully 
reconstituted. In this case, this would only have worked if there was a measurable dose response 
relationship between the inheritance of two permissive alleles (20 % predicted GCT incidence), 
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the heterozygous condition of one permissive and one suppressor allele  (predicted incidence of 
10 % if semi-dominant action, or 0 or 20 % if either permissive or suppressor alleles had 
recessive activity, respectively) or two suppressor alleles (0 % GCT incidence).  Regardless, the 
common paternal suppressor activity of Gct6C57 and Gct6CA identified using SWR-derived 
congenic lines provided strong evidence for a common Gct6 allele or genetic target, which was 
applied in our filtering strategy for the NGS-variants within the mapped Gct6 region. 
The paternal parent-of-origin effect has revealed itself a significant influence for two Gct 
loci, Gct4 and Gct6, on two disparate regions of Chr X.  This cumulative evidence suggests 
biased X-inactivation is in effect for this ovarian tumor-susceptibility phenotype, as opposed to 
allele-specific parent-of-origin expression patterns.  Global X-inactivation bias is not anticipated 
across all tissues of SWR female mice, since inheritance of an X-linked Green fluorescent 
protein (GFP) transgene exhibited appropriate fluorescence mosaicism in the skin of hemizygous 
carrier female pups, whether the transgene was inherited maternally or paternally (Dorward, 
unpublished observations).  It is our current hypothesis that the first ovarian follicle wave is the 
site of the androgen-sensitive activity of the Gct tumor susceptibility genes.  Implementation of 
fluorescent trace analysis to isolate the GC populations from this first wave would permit a more 
sensitive assay for X-inactivation bias in this developmentally-restricted follicle cohort. 
5.2 Gct6 tumor suppressor candidate genes 
Paternal inheritance of either the Gct6CA or Gct6C57 locus on Chr X was sufficient to 
completely or significantly suppress GC tumor initiation in SWR.CAST-X and SWR.C57-X 
females, respectively.  This finding supported the search for Gct6 alleles shared between CAST 
and C57 strains that are unique from the GC tumor permissive strains such as SWR.  A whole-
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locus capture protocol for the Gct6 region of SWR inbred and SWR.CAST-X congenic line 
DNA preceded high-throughput NGS sequencing at TJL.  Post-informatics reports were provided 
to our lab that listed all nucleotide variations between SWR and C57 reference, and between 
CAST and C57 reference genome, with interval boundaries determined by prior phenotype 
mapping studies for Gct6.  It was my role to review the reports, categorize, prioritize and 
independently verify the sequence of variants that were considered promising candidates for 
Gct6 identity. 
The variant report for CAST vs C57 genome contained four times more variants (4,682) 
compared to the SWR vs C57 file (1148 entries), likely due to the highly divergent and 
polymorphic nature of the CAST genome (Figure 1.8). Since the functional testing supported our 
hypothesis that C57 and CAST strains share a common Gct6 allele, or have unique alleles in a 
common gene, my variant analysis proceeded with the shorter variant report (SWR vs C57), after 
which prioritized variants of interest were investigated in the CAST genome. The majority of the 
1148 variants (C57 vs SWR) isolated after multiple filtering steps were intronic 62%) or 
intergenic (28%) and a minority (≈10 %) of the variants were exonic. The absolute GCT 
resistance conferred by Gct6C57 and Gct6CA in the homozygous SWR.C57-X and SWR.CAST-X 
congenic lines, and near-absolute resistance conferred by paternal inheritance of either allele, 
implies a very significant allelic difference exists between the permissive and suppressive 
strains.  For this reason, I originally prioritized the exonic variants for further investigation, since 
both synonymous and nonsynonymous SNP or Insertion/Deletion (INDEL) variations within 
exons can have severe effects on protein-coding genes, including: amino acid exchange in the 
translated protein, premature protein truncation, translation read-through or disrupted transcript 
splicing.  Five exonic, nonsynonymous variants in 5 genes (BC065397, Esx1, Tmsb15l, 
94 
Tmsb15b1, and Slc25153) were verified by independent Sanger sequencing analysis and 
subsequently given priority for the allele segregation analysis between suppressive and 
permissive strain categories. 
The BC065397 gene is not annotated in the human genome and does not have any 
orthologs listed on the Ensembl genome browser (GRCm38; Ensembl Genome Browser release 
75, Flicek et al., 2014). This, together with the lack of allele segregation among GC permissive 
and suppressive strains, made this gene a low priority in regards to a translatable gene candidate 
for human JGCTs as a Gct6 GC tumor suppressor gene. 
Esx1 encodes 65 kDa protein which, upon proteolytic cleavage, produces a 45 kDa N-
terminal fragment and a 20 kDa C-terminal fragment. The 45 kDa fragment has a homeo-domain 
where the 20 kDa fragment has a proline-rich domain. The N-terminal fragment is localized at 
the nucleus while the C-terminal fragment is localized to the cytoplasm. Esx1 is likely to play a 
role in placental development, spermatogenesis and may regulate cell cycle progression and 
transcription during spermatogenesis (Bonaparte et al., 2010). Human and mouse Esx1 proteins 
have a very high sequence divergence of 34 % concentrated mostly at the C-terminal domain 
which plays a role in cell cycle control, suggesting that the region’s function is different in 
primates and rodents (Bonaparte et al., 2010). The allele distribution of this SNP among 
permissive and suppressive strains is diverse; thus, this gene was given a low priority as being 
the candidate gene responsible for the Gct6 tumor suppresser activity. 
Thymosin beta proteins (Tmsb) play important roles in the organization of the 
cytoskeleton and actin polymerization (Ensembl Genome Browser release 75, Flicek et al., 
2014). There is a family of thymosin β genes, a member of which, Thymosin β -4 (Tmsb4x), 
encodes a major actin-sequestering protein that is up-regulated in a wide variety of carcinomas, 
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implicated in motility of certain cancer cells (Wang et al., 2003). The up-regulation of Tmsb4x 
promotes disruption of cell-cell adhesion and activates β-catenin signalling; therefore, it is 
thought to be responsible for the invasive phenotype of human cancers, such as colorectal 
carcinomas (Chen et al., 2004). Human ortholog of Tmsb15l gene, TMSB15A, has been used as 
a predictor of chemotherapy response in triple-negative breast cancer (Darb-Esfahani et al., 
2012).  Since the SNP reported by NGS is located in a highly conserved region of the gene that 
causes an AA change and most likely affect Tmsb15l function, this variant gene was considered 
a good candidate for Gct6 GC tumor suppressor activity. However, the lack of allele co-
segregation with GC permissive and suppressive strains gave Tmsb15l a lower priority in the list 
of gene candidates for shared identity with Gct6. 
The SLC25 family of mitochondrial carriers (MCs) are the largest of solute carriers that 
shuttle a variety of metabolites across the inner mitochondrial membrane (Palmieri, 2013). In 
humans, the SLC25 genes are distributed among all chromosomes; they differ significantly in 
their size and organization. They may contain 1 to 18 exons and spanning 1,184 to 65,456 bp 
(Palmieri, 2013). The expression levels of SLC25 family of genes vary in different tissues; they 
are highly conserved between species and are widespread in eukaryotes, viruses and bacteria 
(Palmieri, 2013). This superfamily are not only limited to mitochondria, as some members of the 
family are located in other cell organelles, such as peroxisomes, chloroplasts and mitosomes. 
MCs are nuclear proteins that are imported from the cytosol into the membrane where they are 
localized; they bridge between the metabolic reactions in the cytosol and mitochondrial matrix 
through the catalysis of numerous solutes translocation across the membrane. MCs are involved 
in many important metabolic pathways: oxidative phosphorylation, synthesis and breakdown of 
mtDNA, mtRNA and mitochondrial proteins, modulation of the nucleotide and deoxynucleotide 
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pools in the mitochondrial matrix, necrosis and apoptotic cell death (Palmieri, 2013). The general 
function of this super family is known, but not all the members of the family have their specific 
functions determined. This is the case for Slc25a53, presently described as an orphan carrier with 
no known substrate. The structure of all SLC25 proteins are very similar as they all have 
common sequences that create tripartite structural features made of a 3-fold repeated signature 
motif and 6 transmembrane α-helices, 2 in each of the 3 repeats (Palmieri, 2013).  The cloning 
and functional identification of many SLC25 genes has made it possible to identify the genes and 
their defects responsible for some diseases (e.g. Stanley syndrome and Amish microcephaly) and 
to understand the molecular basis of the symptoms caused by certain diseases 
(hyperornithinaemia, hyperammonaemia and homocitrullinuria (HHH) syndrome and type II 
citrullinemia; Palmieri, 2013). The Slc25a53 allele association between GC permissive and 
suppressive strains revealed that all the GC permissive strains had an exon-coding deviation, 
either an insertion or a deletion of a repeat, from the Slc25a53 wild type allele present in C57 
and CAST strains. This suggests that Slc25a53 function is compromised in GC permissive 
strains, leading to the development of GC tumors. Therefore, the Slc25a53 gene ranks highly in 
the list of candidate genes as having shared identity with the Gct6 tumor suppressor.  As an 
orphan solute carrier, it is uncertain how a Slc25a53 mutation might contribute to GC tumor 
susceptibility.  Given our knowledge that the juvenile-onset GC tumor initiation is sensitive to 
androgenic stimulation, it could be postulated that Slc25a53 protein activity counters a cellular 
process initiated by androgens in the first follicular wave.  It is part of the future directions for 
the project to examine Slc25a53 protein localization and quantification in the GC populations of 
the strains that are tumor-permissive or tumor-suppressive, to determine if the SWR strain 
represents a spontaneous null strain for this candidate tumor suppressor gene. 
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5.3 Remaining NGS Identified Variants  
Intronic variants can cause abnormal variations in splicing and are proportionally related 
to multiple human genetic disorders; they contribute to the development of cancer if not 
corrected by posttranscriptional quality control mechanism (Chen et al., 2006, Skotheim & Nees, 
2007, He C., et al., 2009 and Fackenthal et al., 2008). Intergenic (non-coding) variants were 
originally thought to serve no purpose and were simply junk sequence. However, comparative 
genomics studies have shown that noncoding DNA sequences can have important functions 
(Ludwig, 2002). For instance, genome-wide association studies have successfully identified an 
intergenic loci located on chromosome 8q24 that harbours an important enhancer element 
associated with multiple cancer types (Grisanzio et al., 2010 and Chiara et al., 2010). Some 
regions of noncoding DNA are highly conserved even after 300–450 million years of evolution, 
implying significant functional constraints (Duret et al., 1997 and Müller et al., 2002). 
Synonymous variants, or silent mutations, are mutations in which the AA sequence is not altered 
lead to a change of one of the letters in the triplet code that represents a codon, but despite the 
single base change, the AA that is coded for remains unchanged or similar in biochemical 
properties. Silent mutations were thought to be of little to no significance. However, recent 
research suggests that such alterations to the triplet code do effect protein translation efficiency 
and protein folding and function (Komar, 2007 and Czech et al. 2010).  
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 6.0 Summary and Future Directions 
The unique congenic line, SWR.C57-X, developed and tested in this research project 
replicated the Gct6 tumor suppressor activity observed for the CAST strain, suggesting Gct6 
suppressor gene targets or alleles are in common between the C57 and CAST genomes.  This 
phenotype information was very useful for our NGS variant filtering strategy of the whole Gct6 
locus between SWR (tumor permissive) and CAST or C57 (tumor suppressive) strains.  My 
participation in the downstream (quaternary) analysis of the NGS variant reports prioritized the 
non-synonymous exonic variants in 5 unique genes within the mapped Gct6 locus boundaries.  
Disruptions (deletions or insertions) in the protein coding region of the gene Slc25a53 were 
identified in all GCT-permissive strains, but not in C57 or CAST strains, making Slc25a53 an 
excellent candidate as a tumor-suppressor gene.   Solute carrier family 25 is a large family of 
substrate-specific carriers found primarily in the mitochondria, but also other organelles.  
Slc25a53 is currently an orphan member of the family, with unknown solute specificity or 
cellular localization.  A future direction for this project is to determine the cellular and tissue 
expression profile for Slc25a53 gene and protein in GCT permissive (SWR) and resistant 
(SWR.C57-X or SWR.CAST-X) congenic lines, to follow up on genetic evidence for Slc25a53 
as the candidate gene for Gct6 identity.   
As the identity of Gct6 is established and confirmed, additional assays will be needed to 
determine how the Gct6 activity influences androgen-driven GCT initiation in this model system.  
Furthermore, the persistence of the dominant paternal parent-of-origin effect with respect to X-
linked Gct loci, now proven in a third congenic line (SWR.C57-X), suggests bias in X-
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inactivation underlies the paternal influence of Gct4 and Gct6.  This is an intriguing concept, 
particularly if this bias is limited to the GC populations of the first follicular wave.   
In summary, the trait of spontaneous GC tumorigenesis observed in the SWR strain 
model represents a unique opportunity to study genetic and endocrine mechanisms related to 
GCT susceptibility. Given the scarcity of information about specific genes associated with 
JGCTs, pursuing genetic determinants in this model provides insight for human pediatric JGCT, 
and may provide mechanistic insights for other androgen-sensitive cancers, such as prostate 
cancer. 
The future directions recommended for continued research progress are: 
 Determine if the SWR strain is a spontaneous, viable, Slc25a53 null strain using gene and 
protein expression analyses.  
 Identify the tissue and cellular expression profile for Slc25a53 in strains (C57, CAST) with 
wild-type alleles. 
 With accumulating evidence for Slc25a53 as a candidate GCT susceptibility gene in the 
SWR model, translational and collaborative exploration in human JGCT specimens (protein 
expression or sequencing analysis) is warranted. 
 The paternal parent-of-origin effect for two physically distant X-linked Gct loci suggests X-
inactivation bias.  This bias could be limited to the first follicular wave of ovarian follicles.  
This research aim could be pursued using fluorescent reporter strains to isolate GC 
populations from the first folliclular wave, followed by gene expression analysis to calculate 
the ratios of X-linked maternal vs. paternal alleles in heterozygous female offspring. 
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Appendix A Esx1 AA alignment conservation among multiple species 
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Protein sequence conservation of Esx1 gene was compared between multiple species. The 
location of the variant detected by NGS is shown in black box and the consequence of the variant 
is shown by the letter above the box. Two species with highest target % ID were chosen from 
each species set (Primates, Rodents, Laurasiatheria, Sauropsida and Fish) for protein sequence 
alignment. Target specie = Mouse, target % ID for: Human = 21, Bushbaby = 40, Tarsier = 31, 
Rat = 80, Squirrel = 39, Cat = 38, Dog = 37. 
 *: identities; -: deletion; gaps: nucleotide changes. RED:  Small and hydrophobic, BLUE: 
Acidic, MAGENTA:  Basic, GREEN:  Hydroxyl, sulfhydryl and amine, Grey: Unusual AA  
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Appendix B Tmsb15l AA alignment conservation among multiple species 
 
 
 
Protein sequence conservation of Tmsb15l gene was compared between multiple species. The 
location of the variant detected by NGS is shown in black box and the consequence of the variant 
is shown by the letter above the box. Two species with the highest target % ID were chosen from 
each species set (Primates, Rodents, Laurasiatheria, Sauropsida and Fish) for protein sequence 
alignment. Target specie = Mouse, target % ID for: Human = 78, Mouse lemur = 85, Orangutan 
= 78, Rat = 89, Rabbit = 80, Hedgehog = 88, Sheep = 80, Turkey = 77, Zebra finch = 76, Platy 
fish = 71, Amazon molly = 71. 
 
*: identities; -: deletion; gaps: nucleotide changes. RED:  Small and hydrophobic, BLUE: Acidic, 
MAGENTA:  Basic, GREEN:  Hydroxyl, sulfhydryl and amine, Grey: Unusual AA 
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Appendix C Slc25a53 AA alignment conservation among multiple species 
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Protein sequence conservation of Slc25a53 gene was compared between multiple species. The 
location of the variant detected by NGS is shown in black box and the consequence of the variant 
is shown by the letter above the box. Two species with the highest target % ID were chosen from 
each species set (Primates, Rodents, Laurasiatheria, Sauropsida and Fish) for protein sequence 
alignment. Target specie = Mouse, target % ID for: Human = 89, Tarsier = 92, Chimpanzee = 90, 
Rat = 98, Squirrel = 90, Cat = 89, Dog = 89, Chinese soft shell turtle = 61, Anole lizard = 46, 
Coelacanth = 54, Tilapia = 46. 
 
*: identities; -: deletion; gaps: nucleotide changes. RED:  Small and hydrophobic, BLUE: Acidic, 
MAGENTA:  Basic, GREEN:  Hydroxyl, sulfhydryl and amine, Grey: Unusual AA 
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